Chapter 30

  1. Abrams-Ogg A, Holmberg DL, Quinn RF, et al. 2002. Blindness now attributed to enrofloxacin therapy in a previously reported case of a cat with acromegaly treated by cryohypophysectomy. Can Vet J 43:53-54.
  2. Acar JF. 2000. Antibiotic synergy and antagonism. Med Clin North Am 84:1391-1406.
  3. Acar JF, Goldstein FW. 1997. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 24(Suppl):S67-S73.
  4. Adams HR, Dixit BN. 1970. Prolongation of pentobarbital by chloramphenicol in dogs and cats. J Am Vet Med Assoc 156:902-905.
  5. Albarellos GA, Kreil VE, Landoni MF. 2004. Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 27:155-162.
  6. Albarellos GA, Landoni MF. 2009. Current concepts on the use of antimicrobials in cats. Vet J 180:304-316.
  7. Albarellos G, Montoya L, Ambros L, et al. 2004. Multiple once-daily dose pharmacokinetics and renal safety of gentamicin in dogs. J Vet Pharmacol Ther 27:21-25.
  8. Albarellos GA, Montoya L, Waxman S, et al. 2006. Ciprofloxacin and norfloxacin pharmacokinetics and prostatic fluid penetration in dogs after multiple oral dosing. Vet J 172:334-339.
  9. Ali MZ, Goetz MB. 1997. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:796-809.
  10. Ambrose PG, Owens RC, Grasela D. 2000. Antimicrobial pharmacodynamics. Med Clin North Am 84:1431-1446.
  11. American Animal Hospital Association. 2008. Guidelines for antimicrobial drugs. Available at http://secure.aahanet.org/eweb/dynamicpage.aspx?site=resources&webcode=BasicGuidelinesofJTUA. Accessed on 12/21/10.
  12. American Association of Feline Practitioners, American Animal Hospital Association. 2006. Basic guidelines of judicious therapeutic use of antimicrobials. Available at http://secure.aahanet.org/eweb/dynamicpage.aspx?site=resources&webcode=BasicGuidelinesofJTUA. Accessed on 12/21/10.
  13. American Veterinary Medical Association. 2005. Judicious therapeutic use of antimicrobials. Available at http://www.avma.org/products/scientific/jtua.asp. Accessed on 12/20/10.
  14. Amstey MS. 2000. Chloramphenicol therapy in pregnancy. Clin Infect Dis 30:237.
  15. Anadon A, Reeves-Johnson L. 1999. Macrolide antibiotics, drug interactions and microsomal enzymes: implications for veterinary medicine. Res Vet Sci 66:197-203.
  16. Andes DR, Craig WA. 1998. Pharmacodynamics of fluoroquinolones in experimental models of endocarditis. Clin Infect Dis 27:47-50.
  17. Angus JC, Spencer SJ, Hirsh DC. 1997. Microbiological study of transtracheal aspirates from dogs with suspected lower respiratory tract disease. 264 cases (1989-1995). J Am Vet Med Assoc 210:55-58.
  18. Anonymous. 1997. Extralabel use of fluoroquinolones prohibited. J Am Vet Med Assoc 211:1106.
  19. Anwar H, Costerton W. 1992. Effective use of antibiotics in the treatment of biofilm-associated infection. ASM News 58:665-668.
  20. Apley MD, Brown SA, Fedorka-Cray PJ, et al. 1998. Role of veterinary therapeutics in bacterial resistance development: animal and public health perspectives. J Am Vet Med Assoc 212:1209-1213.
  21. Albarellos GA, Kreil VE, Landoni MF. 2004.Pharmacokinetics of ciprofloxacin after single intravenous and repeat oral administration to cats. J Vet Pharmacol Ther 27:155-162.
  22. Albarellos GA, Montoya L, Ambros L, et al. 2004. Multiple once-daily dose pharmacokinetics and renal safety of gentamicin in dogs. J Vet Pharmacol Ther 27:21-25.
  23. Antonio O, Weigel LM, Rasheed K, et al. 2002. Mechanisms of decreased susceptibility to cefpodoxime in Escherichia coli. Antimicrob Agents Chemother 46:3829-3836.
  24. Aucoin DP. 1990. Fluoroquinolone antibiotics: use in companion animal medicine, pp 13-23. In Proceedings of the Symposium on Quinolones, Eastern States Veterinary Conference, Orlando, FL.
  25. Aucoin DP, Hardie L, Bissonette K, et al. 1991. Disposition and efficacy study of enrofloxacin in 18 canine patients with multiresistant bacterial infections. Abstract no 99. J Am Coll Vet Intern Med 5:138.
  26. Authier S, Paquette D, Labrecque O, et al. 2006. Comparison of susceptibility to antimicrobials of bacterial isolates from companion animals in a veterinary diagnostic laboratory in Canada between 2 time points 10 years apart. Can Vet J 47:774-778.
  27. Baden LR. 2005. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052-1054.
  28. Bailey TC, Little JR, Littenberg B, et al. 1997. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 24:786-795.
  29. Ball KR, Rubin JE, Chirino-Trejo M, et al. 2008. Antimicrobial resistance and prevalence of canine uropathogens at the Western College of Veterinary Medicine Veterinary Teaching Hospital, 2002-2007. Can Vet J 49:985-990.
  30. Barbhaiya RH, Wang L, Shuy WC, et al. 1992. Absolute bioavailability of cefprozil after oral administration in beagles. Antimicrob Agents Chemother 36:687-689.
  31. Bark H, Perk R. 1995. Fanconi syndrome associated with amoxicillin therapy in a dog. Canine Pract 20:19-22.
  32. Barker CW, Zhang W, Sanchez S, et al. 2003. Pharmacokinetics of imipenem in dogs. Am J Vet Res 64:694-699.
  33. Bartlett JG. 2000. Update in infectious diseases. Ann Intern Med 133:285-292.
  34. Barton MD. 2001. Is it reasonable to use third-generation cephalosporins to treat animals? Aust Vet J 79:620.
  35. Baş LA, Simşek A, Corlu M, et al. 2002. Determination of intracellular concentrations of free and two types of liposome-encapsulated enrofloxacin in Anatolian shepherd dog monocytes. J Vet Med B Infect Dis Vet Public Health 49:289-293.
  36. Batzias GC, Delis GA, Koutsoviti-Papadopoulou M. 2004. A new HPLC/UV method for the determination of clindamycin in dog blood serum. J Pharm Biomed Anal 35:545-554.
  37. Bayden LR. 2005. Prophylactic antimicrobial agents and the importance of fitness. N Engl J Med 353:1052-1054.
  38. Bayer Corporation. 1998. Baytril material safety data sheet. Shawnee Mission, KS.
  39. Bayer Healthcare. 2010. Enrofloxacin package insert. Bayer Healthcare. Toronto, Ont., Can. Available at http://www.baytril.com/. Accessed on 12/20/10.
  40. Beatty JA, Swift N, Foster DJ, et al. 2006. Suspected clindamycin-associated oesophageal injury in cats: five cases. J Feline Med Surg 8:412-419.
  41. Beningo KE, Scott DW, Miller WH Jr, et al. 1999. Observations on the use of tetracycline and niacinamide as antipruritic agents in atopic dogs. Can Vet J 40:268-270.
  42. Bennett SL. 2007. Photosensitisation induced by clofazimine in a cat. Aust Vet J 85:375-380.
  43. Bensignor E, Gauguere E. 2004. Treatment of canine acne with doxycycline: an open trial, poster 7. Vet Dermatol 15(Suppl 1):43.
  44. Berger SL, Scagliotti RH, Lund EM. 1995. A quantitative study of the effects of Tribrissen on canine tear production. J Am Anim Hosp Assoc 31:236-241.
  45. Bettenay SV, Lappin MR, Mueller RS. 2007. An immunohistochemical and polymerase chain reaction evaluation of feline plasmacytic pododermatitis. Vet Pathol 44:50-53.
  46. Bettenay SV, Mueller RS, Dow K, et al. 2003. Prospective study of the treatment of feline plasmacytic pododermatitis with doxycycline. Vet Rec 152:564-566.
  47. Bialer M, Wu WH, Look ZM, et al. 1987. Pharmacokinetics of cefixime after oral and intravenous doses in dogs: bioavailability assessment for a drug showing nonlinear serum protein binding. Res Commun Chem Pathol Pharmacol 56:21-32.
  48. Bidgood TL, Papich MG. 2002. Plasma pharmacokinetics and tissue fluid concentrations of meropenem after intravenous and subcutaneous administration in dogs. Am J Vet Res 63:1622-1628.
  49. Bidgood TL, Papich MG. 2003. Comparison of plasma and interstitial fluid concentrations of doxycycline and meropenem following constant rate intravenous infusion in dogs. Am J Vet Res 64:1040-1046.
  50. Bidgood TL, Papich MG. 2005. Plasma and interstitial fluid pharmacokinetics of enrofloxacin, its metabolite ciprofloxacin, and marbofloxacin after oral administration and a constant rate intravenous infusion in dogs. J Vet Pharmacol Ther 28:329-341.
  51. Birkenheuer AJ, Levy MG, Breitschwerdt EB. 2004. Efficacy of combined atovaquone and azithromycin for therapy of chronic Babesia gibsoni (Asian genotype) infections in dogs. J Vet Intern Med 18:494-498.
  52. Bloom PB, Rosser EJ. 2001. Efficacy of once-daily clindamycin hydrochloride in the treatment of superficial bacterial pyoderma in dogs. J Am Anim Hosp Assoc 37:537-542.
  53. Boeckh A, Boothe DM, Wilkie S. 1999. Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs. From the Proceedings from the Third International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21:40-43.
  54. Boeckh A, Boothe D, Wilkie S, et al. 2001. Time course of enrofloxacin and its active metabolite in peripheral leukocytes of dogs. Vet Ther 2:334-344.
  55. Boeckh M, Lode H, Deppermann KL, et al. 1990. Pharmacokinetics and serum bactericidal activities of quinolones in combination with clindamycin, metronidazole, and ornidazole. Antimicrob Agents Chemother 34:2407-2414.
  56. Bone RC. 1991. A critical evaluation of new agents for the treatment of sepsis. JAMA 266:1686-1691.
  57. Boothe DM. 1989. The practical aspects of treating bacterial infections in cats. Vet Med 84:884-904.
  58. Boothe DM. 1996. Antimicrobial therapy in the critically ill patient. Compend Cont Educ Pract Vet 18(Suppl):66-83.
  59. Boothe DM. 2000. Optimizing antibacterial therapy for small animals using the professional flexible label, Bayer Selected Proc TNAVC. Compend Cont Educ Pract Vet 22(Suppl):26-32.
  60. Boothe DM. 2001. Antimicrobial drugs, pp 150-173. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 1. WB Saunders, Philadelphia.
  61. Boothe DM. 2001. Principles of antimicrobial therapy, pp 125-149. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 1. WB Saunders, Philadelphia.
  62. Boothe DM. 2006. Principles of antimicrobial therapy. Vet Clin Small Anim Pract 36:1003-1047.
  63. Boothe DM. 2010. Personal communication. College of Veterinary Medicine, Auburn University, Auburn, AL.
  64. Boothe DM. 2012. Antimicrobial Drugs, pp 189-269. In Booth DM (ed): Small animal clinical pharmacology and therapeutics, ed 3. WB Saunders, Philadelphia.
  65. Boothe DM, Boeckh A, Boothe H. 2009. Evaluation of the distribution of enrofloxacin by circulating leukocytes to sites of inflammation in dogs. Am J Vet Res 70:16-22.
  66. Boothe DM, Boeckh A, Boothe HW, et al. 2001. Tissue concentrations of enrofloxacin and ciprofloxacin in anesthetized dogs following single intravenous administration. Vet Ther 2:120-128.
  67. Boothe DM, Boeckh A, Boothe HW, et al. 2002. Plasma concentrations of enrofloxacin and its active metabolite ciprofloxacin in dogs following single oral administration of enrofloxacin at 7. 5, 10, or 20 mg/kg. Vet Ther 3:409-419.
  68. Boothe DM, Boeckh A, Simpson RB, et al. 2006. Comparison of pharmacodynamic and pharmacokinetic indices of efficacy for 5 fluoroquinolones toward pathogens of dogs and cats. J Vet Intern Med 20:1297-1306.
  69. Boothe DM, Boothe HW. 1999. Serum and tissue concentrations of enrofloxacin in dogs. From the Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Suppl Compend Cont Educ Pract Vet 21:33-39.
  70. Boothe DM, Hubka P. 2010. Fosfomycin: An alternative drug for treatment of E. coli urinary tract infections? Proceedings ACVIM Forum, June 9-12, Anaheim, CA.
  71. Boothe DM, Brown SA, Fate GD, et al. 1996. Plasma disposition of clindamycin microbiological activity in cats after single oral doses of clindamycin hydrochloride as either capsule or aqueous solution. J Vet Pharmacol Ther 19:491-494.
  72. Boweersock TL, Wu CC, Inskeep GA, et al. 2000. Prevention of bacteremia in dogs undergoing dental scaling by prior administration of oral clindamycin of chlorhexidine oral rinse. J Vet Dent 17:11-16.
  73. Brandt KD. 1995. Modification by oral doxycycline administration of articular cartilage breakdown in osteoarthritis. J Rheumatol 22(Suppl 43):149-151.
  74. Brogan JC. 1992. Sorting out the cephalosporins. Postgrad Med 91:301-315.
  75. Brooks MB, Morley PS, Dargatz DA, et al. 2003. Survey of antimicrobial susceptibility testing practices of veterinary diagnostic laboratories in the United States. J Am Vet Med Assoc 222:168-173.
  76. Brooks AK, Zervos MJ. 1998. New antimicrobial agents for gram-positive infections. Cur Opinion Infect Dis 11:667-671.
  77. Brothers AM, Gibbs PS, Wooley RE. 2002. Development of resistant bacteria isolated from dogs with otitis externa or urinary tract infections after exposure to enrofloxacin in vitro. Vet Ther 3:493-500.
  78. Brown SA, Arnold TS, Hamlow PJ, et al. 1995. Plasma and urine disposition and dose proportionality of ceftiofur and metabolites in dogs after subcutaneous administration of ceftiofur sodium. J Vet Pharmacol Ther 18:363-369.
  79. Brown SA, Dieringer TM, Hunter RP, et al. 1989. Oral clindamycin disposition after single and multiple doses in normal cats. J Vet Pharmacol Ther 12:209-216.
  80. Brown SA, Nelson RW, Moncrieff CS. 1991. Gentamicin pharmacokinetics in diabetic dogs. J Vet Pharmacol Ther 14:90-95.
  81. Bryskier A. 1998. Novelties in the field of anti-infectives in 1997. Clin Infect Dis 27:865-883.
  82. Bryskier A. 2000. Novelties in the field of anti-infectives in 1999. Clin Infect Dis 31:1423-1466.
  83. Budsberg SC, Gallo JM, Starliper CE, et al. 1991. Comparison of cortical bone and serum concentrations of clindamycin achievable by direct local infusion and intravenous administration. J Orthop Res 9:594-599.
  84. Budsberg SC, Kemp DT. 1990. Antimicrobial distribution and therapeutics in bone. Compend Cont Educ Pract Vet 12:1758-1763.
  85. Budsberg SC, Walker RD, Slusser P, et al. 1989. Norfloxacin therapy in infections of the canine urogenital tract caused by multiresistant bacteria. J Am Vet Med Assoc 25:713-716.
  86. Burkhardt JE, Hill MA, Carlton WW, et al. 1990. Histologic and histochemical changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 27:162-170.
  87. Burkhardt JE, Hill MA, Turek JJ, et al. 1992. Ultrastructural changes in articular cartilages of immature beagle dogs dosed with difloxacin, a fluoroquinolone. Vet Pathol 29:230-238.
  88. Burkhardt JE, Walterspiel JN, Schaad UB. 1997. Quinolone arthropathy in animals versus children. Clin Infect Dis 25:1196-1204.
  89. Campbell BG, Rosin E. 1998. Effect of food on absorption of cefadroxil and cephalexin in dogs. J Vet Pharmacol Ther 21:418-420.
  90. Carbon C. 1998. Pharmacodynamics of macrolides, azalides, and streptogramins: effect on extracellular pathogens. Clin Infect Dis 27:28-32.
  91. Carbone M, Pennisi MG, Masucci M, et al. 2001. Activity and postantibiotic effect of marbofloxacin, enrofloxacin, difloxacin and ciprofloxacin against feline Bordetella bronchiseptica isolates. Vet Microbiol 81:79-84.
  92. Carli S, Anfossi P, Villa R, et al. 1999. Absorption kinetics and bioavailability of cephalexin in the dog after oral and intramuscular administration. J Vet Pharmacol Ther 22:308-313.
  93. Carlotti DN. 1996. New trends in systemic antibiotic therapy of bacterial skin disease in dogs. Compend Cont Educ Pract Vet 18:40-47.
  94. Carlotti DN, Jasmin P, Gardey L, et al. 2004. Evaluation of cephalexin intermittent therapy (weekend therapy) in the control of recurrent idiopathic pyoderma in dogs: a randomized, double-blinded, placebo-controlled study. Vet Dermatol 15(Suppl 1):8-9.
  95. Carson JL, Strom BL, Duff A, et al. 1993. Acute liver disease associated with erythromycins, sulfonamides, and tetracyclines. Ann Intern Med 119:576-583.
  96. Cassell GH. 1995. ASM task force urges broad program on antimicrobial resistance. ASM News 61:116-120.
  97. Castells G, Capece BPS, Pérez F, et al. 2001. Allometric analysis of thiamphenicol disposition among seven mammalian species. J Vet Pharmacol Ther 24:193-197.
  98. Castells G, Intorre L, Franquelo C, et al. 1998. Pharmacokinetics of thiamphenicol in dogs. Am J Vet Res 59:1473-1475.
  99. Cattin I, Liehmann L, Ammon P, et al. 2008. Subcutaneous abscess caused by Clostridium perfringens and osteomyelitis in a dog. J Small Anim Pract 49:200-203.
  100. Caylor KB, Cassimatis MK. 2001. Metronidazole neurotoxicosis in two cats. J Am Anim Hosp Assoc 37:258-262.
  101. Cester CC, Schneider M, Toutain PL. 1996. Comparative kinetics of 2 orally administered fluoroquinolones in dogs—enrofloxacin versus marbofloxacin. Rev Med Vet 147:703-716.
  102. Cester CC, Toutain PL. 1997. A comprehensive model for enrofloxacin to ciprofloxacin transformation and disposition in the dog. J Pharmaceut Sci 86:1148-1155.
  103. 102a. Chandler HL, Gemensky-Metzler AJ, Bras ID, et al. 2010. In vivo effects of adjunctive tetracycline treatment on refractory corneal ulcers in dogs. J Am Vet Med Assoc 237:378-386.
  104. Chapman J, Mense M, Dubey JP. 2005. Clinical muscular sarcocystosis in a dog. J Parasitol 91:187-190.
  105. Chaudhary U, Aggarwal R. 2004. Extended spectrum β-lactamases (ESBL)—an emerging threat to clinical therapeutics. Indian J Med Microbiol 22:75-80.
  106. Cherni JA, Boucher JF, Skogerboe TL, et al. 2006. Comparison of the efficacy of cefpodoxime proxetil and cephalexin in treating bacterial pyoderma in dogs. Intern J Appl Res Vet Med 4:85-93.
  107. Chia JK, Nakata MM, Lami JL, et al. 1998. Azithromycin for the treatment of cat-scratch disease. Clin Infect Dis 26:193-194.
  108. Chretin JD, Rassnick KM, Shaw NA, et al. 2007. Prophylactic trimethoprim-sulfadiazine during chemotherapy in dogs with lymphoma and osteosarcoma: a double-blind, placebo-controlled study. J Vet Intern Med 21:141-148.
  109. Christ W. 1990. Central nervous system toxicity of quinolones: human and animal findings. J Antimicrob Chemother 26:219-225.
  110. CIJIG Communique. 2001. National Summit on Antibiotic Resistance. Available at http://www.health.gov.au/internet/main/publishing.nsf/content/EA33D21F7C12F3D8CA256F1900052727/$File/cijigcom.pdf. Accessed on 12/20/10.
  111. Clarke CR. 2006. Antimicrobial resistance. Vet Clin Small Anim 36:987-1001.
  112. Cockcroft PD, Jones AC, Harris JM. 2003. Antibacterial activity of ceftiofur-impregnated polymethylmethacrylate beads following manufacture, storage and sterilization. Vet Rec 152:21-22.
  113. Coelho DD. 1997. Metronidazole resistant trichomoniasis successfully treated with paromomycin. Genitourin Med 73:397-398.
  114. Cohn LA, Gary AT, Fales WH, et al. 2003. Trends in fluoroquinolone resistance of bacteria isolated from canine urinary tracts. J Vet Diagn Invest 15:338-343.
  115. Cole LK, Kwochka KW, Hillier A, et al. 2006. Ciprofloxacin as a representative of disk diffusion in vitro susceptibility of enrofloxacin for bacterial organisms from the middle-ear tissue of dogs with end-stage otitis externa. Eur Soc Vet Dermatol 17:128-133.
  116. Cole LK, Kwochka KW, Kowalski JJ, et al. 1998. Microbial flora and antimicrobial susceptibility testing of isolated pathogens from the horizontal ear canal and middle ear in dogs with otitis media. J Am Vet Med Assoc 212:534-538.
  117. Collignon P. 2000. Antimicrobial resistance. Emerg Infect Dis 6:434-436.
  118. Conrads G, Citron DM, Goldstein EJC. 2005. Genetic determinant of intrinsic quinolone resistance in Fusobacterium canifelinum. Antimicrob Agents Chemother 49:434-437.
  119. Conzelman GM. 1980. Pharmacotherapeutics of aminoglycoside antibiotics. J Am Vet Med Assoc 176:1078-1080.
  120. Cooke CL, Singer RS, Jang SS, et al. 2002. Enrofloxacin resistance in Escherichia coli isolated from dogs with urinary tract infections. J Am Vet Med Assoc 220:190-192.
  121. Copeland DD. 2002. Bayer clarifies Baytril status. Vet Pract News Feb:6-7.
  122. Cotard JP, Gruet P, Pechereau D, et al. 1995. Comparative study of marbofloxacin and amoxicillin-clavulanic acid in the treatment of urinary tract infection in dogs. J Small Anim Pract 36:349-353.
  123. Coulet M, Cox P, Lohuis J. 2005. Pharmacodynamics of ibafloxacin in micro-organisms isolated from cats. J Vet Pharmacol Ther 28:29-36.
  124. Coulet M, Morello C, Cox P, et al. 2005. Pharmacokinetics of ibafloxacin in healthy cats. J Vet Pharmacol Ther 28:37-44.
  125. Coulet M, Van Borssum Waalkes M, Cox P, et al. 2002. In vitro and in vivo pharmacodynamic properties of the fluoroquinolone ibafloxacin. J Vet Pharm Ther 25:401-411.
  126. Coulet M, Van Borssum Waalkes M, Leeuwenkamp OR, et al. 2002. Pharmacokinetics of ibafloxacin following intravenous and oral administration to healthy beagle dogs. J Vet Pharmacol Ther 25:89-97.
  127. Cowan RH, Jukkola AF, Arant BS. 1980. Pathophysiologic evidence of gentamicin nephrotoxicity in neonatal puppies. Pediatr Res 14:1204-1211.
  128. Craig WA. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1-12.
  129. Craig WA. May 1999. The mathematics of antimicrobials. The Pfizer/IDCP Discovery Series: Turning Points in Infectious Diseases, article no 18.
  130. Cribb AE. 1989. Idiosyncratic reactions to sulfonamides in dogs. J Am Vet Med Assoc 195:1612-1614.
  131. Cribb AE, Spielberg SP. 1990. An in vitro investigation of predisposition to sulphonamide idiosyncratic toxicity in dogs. Vet Res Commun 14:241-252.
  132. Crispin SM, Gould DJ, Carter WJ, et al. 2002. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 146:555-556.
  133. Culham N, Rawlings JM. 1998. Oral malodor and its relevance to periodontal disease in the dog. J Vet Dent 15:165-168.
  134. Cunha BA. 2000. Minocycline versus doxycycline in the treatment of Lyme neuroborreliosis. Clin Infect Dis 30:237-238.
  135. Dalvie DK, Khosla NB, Navetta KA, et al. 1996. Metabolism and excretion of trovafloxacin. Drug Metabol Dispos 24:1231-1240.
  136. Dancer SJ. 2001. The problem with cephalosporins. J Antimicrob Chemother 48:463-478.
  137. Davis L. 1984. Hypersensitivity reactions induced by antimicrobial drugs. J Am Vet Med Assoc 185:1131-1136.
  138. De Graef EM, Decostere A, Devriese LA, et al. 2004. Antibiotic resistance among fecal indicator bacteria from healthy individually owned and kennel dogs. Microb Drug Resist 10:65-69.
  139. Deldar A, Lewis H, Bloom J, et al. 1988. Cephalosporin-induced changes in the ultrastructure of canine bone marrow. Vet Pathol 25:211-218.
  140. Delmage DA, Payne-Johnson CE. 1991. Erythema multiforme in a Doberman on trimethoprim-sulphamethoxazole therapy. J Small Anim Pract 32:635-639.
  141. DeManuelle TC, Ihrke PJ. 1999. Comparison of enrofloxacin skin concentrations in normal dogs and in dogs with pyoderma. Compend Cont Educ Pract Vet 21(Suppl):50-56.
  142. DeManuelle TC, Ihrke PJ. 1999. Comparison of enrofloxacin skin concentrations in normal dogs and in dogs with pyoderma. From the Proceedings of the Third International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 21(Suppl):49-56.
  143. DeManuelle TC, Ihrke PJ, Brandt CM, et al. 1998. Determination of skin concentrations of enrofloxacin in dogs with pyoderma. Am J Vet Res 59:1599-1604.
  144. Diehl KJ, Roberts SM. 1991. Keratoconjunctivitis sicca in dogs associated with sulfonamide therapy: 16 cases (1980-1990). Prog Comp Ophthalmol 1:276-282.
  145. Dimitrova DJ, Pashov DA, Dimitrov DS. 1998. Dicloxacillin pharmacokinetics in dogs after intravenous, intramuscular and oral administration. J Vet Pharmacol Ther 21:414-417.
  146. DiNubile MJ. 1990. Antibiotics: the antipyretics of choice. Am J Med 89:787-788.
  147. Dodds WJ. 1990. Side effects associated with trimethoprim-sulfa drugs. Adv Small Anim Med Surg 3:5-7.
  148. Dodds WJ. 1990. Sulfonamides and blood dyscrasias. J Am Vet Med Assoc 196:681-682.
  149. Dodds WJ. 1993. Hemorrhagic complications attributable to certain drugs [letter, comments]. J Am Vet Med Assoc 202:702-703.
  150. Doherty T. 1982. Isoniazid poisoning in a dog. Vet Rec 111:460-461.
  151. Dooley DP. 1998. Revisiting doxycycline. Arch Intern Med 158:1469-1470.
  152. Dorfman M, Barsanti J, Budsberg SC. 1995. Enrofloxacin combinations in dogs with normal prostate and dogs with chronic bacterial prostatitis. Am J Vet Res 56:386-390.
  153. Dossin O, Gruet P, Thomas E. 1998. Comparative field evaluation of marbofloxacin tablets in the treatment of feline upper respiratory infections. J Small Anim Pract 39:286-289.
  154. Dow SW, Papich MG. 1991. An update on antimicrobials: new uses, modifications and developments. Vet Med 86:707-715.
  155. Dowers KL, Oliver C, Radecki SV, et al. 2002. Use of enrofloxacin for treatment of large-form Haemobartonella felis in experimentally infected cats. J Am Vet Med Assoc 221:250-253.
  156. Dowers KL, Tasker S, Radecki SV, et al. 2009. Use of prodofloxacin to treat experimentally induced Mycoplasma haemofelis infection in cats. Am J Vet Res 70:105-111.
  157. Dowling PM. 1996. Rational antimicrobial therapy. Can Vet J 37:246-249.
  158. Dowling PM. 2006. Editorial: limiting antimicrobial resistance—your mother was right! J Vet Intern Med 20:1-2.
  159. 157a. Dreyfuss J, Singhvi SM, Shaw JM, et al. 1979. Metabolism of tritium- and carbon-14-labeled tiamulin in dogs, rats, and pigs. J Antibiotic 32:496-503.
  160. Drlica K. 2003. The mutant selection window and antimicrobial resistance. J Antimicrob Chem 52:11-17.
  161. Drlica K, Zhao X, Blondeau JM, et al. 2006. Low correlation between MIC and mutant prevention concentration. Antimicrob Agents Chemother 50:403-404.
  162. Drucker DJ. 2002. Biological actions and therapeutic potential of the glucagons-like peptides. Gastroenterology 122:531-544.
  163. Duval JM, Budsberg SC. 1995. Cortical bone concentrations of enrofloxacin in dogs. Am J Vet Res 56:188-192.
  164. Eddlestone SM, Diniz PPVP, Neer TM, et al. 2007. Doxycycline clearance of experimentally induced chronic Ehrlichia canis infection in dogs. J Vet Intern Med 21:1237-1242.
  165. Edwards D, Rodan I, Tuzio H, et al. 2001. Position Statement of the American Association of Feline Practitioners: Basic guidelines of judicious therapeutic use of antimicrobials in cats. Available at http://www.catvets.com/professionals/guidelines/publications/?Id=179. Accessed 12/20/10.
  166. Ehinger AM, Meyer-Lindenberg A, Vick M, et al. 2002. Concentration of enrofloxacin and its metabolite ciprofloxacin in canine matrices of the locomotor system. J Vet Med A 49:99-104.
  167. Elanco Animal Health. 2005. Micotil 300 injection—product information. Elanco Animal Health, Indianapolis, IN.
  168. El Bahri L, Blouin A. 1991. Fluoroquinolones: a new family of antimicrobials. Compend Cont Educ Pract Vet 13:1429-1434.
  169. Eliopoulos GM. 2003. Quinupristin-dalfopristin and linezolid: evidence and opinion. Clin Infect Dis 36:473-481.
  170. Eriksson A, Rauraama V, Happonen I, et al. 1990. Feeding reduces the absorption of erythromycin in the dog. Acta Vet Scand 31:497-499.
  171. Entenza JM, Moreillon P. 2009. Tigecycline in combination with other antimicrobials: a review of in vitro animal and case report studies. Int J Antimicrob Agents 34:8.e1-8.e9.
  172. European Medicine Agency (EMEA). 2007. Refsal CVMP assessment report for Veraflox. EMEA, London.
  173. Faires MC, Tater KC, Weese JS. 2009. An investigation of methicillin-resistant Staphylococcus aureus colonization in people and pets in the same household with an infected person or infected pet. J Am Vet Med Assoc 235:540-543.
  174. Fantin B, Duval X, Massias L. et al. 2009. Ciprofloxacin dosage and emergence of resistance in human commensal bacteria. J Infect Dis 200:390-398.
  175. Farca AM, Cavana P, Robino P, et al. 2007. In vitro antimicrobial activity of marbofloxacin and enrofloxacin against bacterial strains isolated from companion animals. Schweiz Arch Tierheilkd 149:265-271.
  176. Farca AM, Nebbia P, Re G. 1993. Potentiation of the in vitro activity of some antimicrobial agents against selected gram-negative bacteria by EDTA-tromethamine. Vet Res Commun 17:77-84.
  177. Farca AM, Piromalli G, Maffei F, et al. 1997. Potentiating effect of EDTA-Tris on the activity of antibiotics against resistant bacteria associated with otitis, dermatitis, and cystitis. J Small Anim Pract 38:243-245.
  178. Féria C, Ferreira E, Correia JD, et al. 2002. Patterns and mechanisms of resistance to beta-lactams and beta-lactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J Antimicrob Chemother 49:77-85.
  179. Fidler DP. 1998. Legal issues associated with antimicrobial drug resistance. Emerg Infect Dis 4:169-177.
  180. Filigrove KL, Pakhomova S, Schaab MR, et al. 2007. Structure and mechanism of the genomically encoded fosfomycin resistance protein, FosXZ, from Listeria monocytogenes. Biochemistry 46:811-8120.
  181. Ford MM, Dubielzig RR, Giuliano EA, et al. 2007. Ocular and systemic manifestations after oral administration of a high dose of enrofloxacin in cats. Am J Vet Res 68:190-202.
  182. Forsyth SF, Ilkiw JE, Hildebrand SV. 1990. Effect of gentamicin administration on the neuromuscular blockade induced by atracurium in cats. Am J Vet Res 51:1675-1678.
  183. Fox JL. 2001. Report says Ag antibiotic use and impact on resistance are high. ASM News 67:128-129.
  184. Frank A, Egenvall A. 1994. Sulphanilamide toxicity and crystalluria in a dog after suspected ingestion of a wound treatment ointment. J Small Anim Pract 35:531-534.
  185. Frank I, Lahav D, Aroch I. 2002. Myocardial necrosis and severe metabolic acidosis associated with isoniazid poisoning in a dog. Vet Rec 151:638-639.
  186. Frank LA, Hnilica KA, May ER, et al. 2005. Effects of sulfamethoxazole-trimethoprim on thyroid function in dogs. Am J Vet Res 66:256-259.
  187. Frazier DL, Thompson L, Trettien A, et al. 2000. Comparison of fluoroquinolone pharmacokinetic parameters after treatment with marbofloxacin, enrofloxacin, and difloxacin in dogs. J Vet Pharmacol Ther 23:293-302.
  188. Fridkin SK. 2003. Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 36:1438-1444.
  189. Fujii T, Takatsu S, Stegemann M, et al. 2007. Clinical efficacy and safety of an injectable formulation of cefovecin in the treatment of bacterial skin infections of dogs. Jpn J Vet Derm 13:81-88.
  190. Gabriel A, van den Ingh TSGAM, Clercx C, et al. 2006. Suspected drug-induced destructive cholangitis in a young dog. J Small Anim Pract 47:344-348.
  191. Ganière JP; Médaille C; Etoré F. 2004. In vitro antimicrobial activity of orbifloxacin against Staphylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci 77:67-71.
  192. Ganière JP, Médaille C, Limet A, et al. 2001. Antimicrobial activity of enrofloxacin against Staphylococcus intermedius strains isolated from canine pyodermas. Vet Dermatol 12:171-175.
  193. Gardner SY, Papich MG. 2001. Comparison of cefepime pharmacokinetics in neonatal foals and adult dogs. J Vet Pharmacol Ther 24:187-192.
  194. Garg RC, Keefe TJ, Vig MM. 1987. Serum levels and pharmacokinetics of ticarcillin and clavulanic acid in dog following parenteral administration of Timentin. J Vet Pharmacol Ther 10:324-330.
  195. Gelatt KN, van der Woerdt A, Ketring KL, et al. 2001. Enrofloxacin-associated retinal degeneration in cats. Vet Ophthalmol 4:99-106.
  196. Gelling L, Rothrock G, Reingold A. 1999. Geographic variation in penicillin resistance in Streptococcus pneumoniae: selected sites, United States, 1997. MMWR 48:656-661.
  197. Gengler B. 2000. Systemic antibiotics in veterinary dentistry. Vet Pract News Sept:44.
  198. Gerhardt N, Schulz BS, Werckenthin C, et al. 2006. Pharmacokinetics of enrofloxacin and its efficacy in comparison with doxycycline in the treatment of Chlamydophila felis infection in cats with conjunctivitis. Vet Rec 159:591-594.
  199. German AJ, Cannon MJ, Dye C, et al. 2005. Oesophageal stricture in cats associated with doxycycline therapy. J Feline Med Surg 7:33-41.
  200. Gilbert DN. 1991. Once-daily aminoglycoside therapy. Antimicrob Agents Chemother 35:399-405.
  201. Giamarellou H, Antoniadou A. 2001. Antipseudomonal antibiotics. Med Clin North Am 85:19-42.
  202. Gill HJ, Hough SJ, Naisbitt DJ, et al. 1997. The relationship between the disposition and immunogenicity of sulfamethoxazole in the rat. J Pharmacol Exp Ther 282:795-801.
  203. Giuliano EA, van der Woerdt A. 1998. Feline retinal degeneration: clinical experience and new findings (1994-1997). J Am Anim Hosp Assoc 35:51-514.
  204. Goldstein EJ, Citron DM, Merriam CV, et al. 1999. Activities of telithromycin (HMR 3647, RU 66647) compared to those of erythromycin, azithromycin, clarithromycin, roxithromycin, and other antimicrobial agents against unusual anaerobes. Antimicrob Agents Chemother 43:2801-2805.
  205. Goldstein EJC, Citron DM, Hudspeth M, et al. 1998. Trovafloxacin compared with levofloxacin, ofloxacin, ciprofloxacin, azithromycin and clarithromycin against unusual aerobic and anaerobic human and animal bite-wound pathogens. J Antimicrob Chemother 41:391-396.
  206. Gookin JL, Riviere JE, Gilger BC, et al. 1999. Acute renal failure in four cats treated with paromomycin. J Am Vet Med Assoc 215:1821-1823.
  207. Gookin JL, Trepanier LA, Bunch SE. 1999. Clinical hypothyroidism associated with trimethoprim-sulfadiazine administration in a dog. J Am Vet Med Assoc 214:1028-1031.
  208. Gottlieb S, Wigney DI, Martin PA, et al. 2008. Susceptibility of canine and feline Escherichia coli and canine Staphylococcus intermedius isolates to fluoroquinolones. Aust Vet J 86:147-152.
  209. Gottlieb T, Collignon PJ, Robson JM, et al. 2008. Prevalence of antimicrobial resistances in Streptococcus pneumoniae in Australia, 2005. Report from the Australian Group on Antimicrobial Resistance. Commun Dis Intell 32:242-249.
  210. 207a. Govendir M, Hansen T, Kimble B, et al. 2011. Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin. Vet Microbiol 147:113-118.
  211. Graham JP, Lipman AH, Newell SM, et al. 2000. Esophageal transit of capsules in clinically normal cats. Am J Vet Res 61:655-657.
  212. Grauer GF, Greco DS, Behrend EN, et al. 1994. Effects of dietary protein conditioning on gentamicin-induced nephrotoxicosis in healthy male dogs. Am J Vet Res 55:90-97.
  213. Grauer GF, Greco DS, Behrend EN, et al. 1995. Estimation of quantitative enzymuria in dogs with gentamicin-induced nephrotoxicosis using urine enzyme/creatinine ratios from spot urine samples. J Vet Intern Med 9:324-327.
  214. Grave K, Tanem H. 1999. Compliance with short-term oral antibacterial drug treatment in dogs. J Small Anim Pract 40:158-162.
  215. Gray A. 1990. Trimethoprim-sulphonamide hypersensitivity in dogs [letter, comments]. Vet Res 127:459-460.
  216. Greene CE, Brockus CW, Currin MP, et al. 2002. Basidiobolus ranarum infection in two dogs. J Am Vet Med Assoc 221:528-532.
  217. Greene CE, Ferguson DC. 1990. Antibacterial chemotherapy, pp 461-493. In Greene CE (ed): Infectious diseases of the dog and cat, ed 1. WB Saunders, Philadelphia.
  218. Greene CE, Lappin MR, Marks AM. 1992. Clindamycin in cats. J Am Anim Hosp Assoc 28:323-326.
  219. Greene CE, Watson ADJ. 1998. Antibacterial chemotherapy, pp 185-205. In Greene CE (ed): Infectious diseases of the dog and cat, ed 2. WB Saunders, Philadelphia.
  220. Grønvold AM, L’abée-Lund TM, Sørum H, et al. 2010. Changes in fecal microbiota of healthy dogs administered amoxicillin. FEMS Microbiol Ecol 71:313-326.
  221. Gruet P, Richard P, Thomas E, et al. 1997. Prevention of surgical infections in dogs with a single intravenous injection of marbofloxacin: an experimental model. Vet Rec 140:199-202.
  222. Gunn-Moore DA, Jenkins JA, Lucke VM. 1996. Feline tuberculosis: a literature review and discussion of 19 cases caused by an unusual mycobacterial variant. Vet Rec 138:53-58.
  223. Gutierrez OL, Ocampo CL, Aguilera JR, et al. 2008. Pharmacokinetics of disodium-fosfomycin in mongrel dogs. Res Vet Sci 85:156-161.
  224. Haburjak JJ, Spangler WL. 2002. Isoniazid-induced seizures with secondary rhabdomyolysis and associated acute renal failure in a dog. J Small Anim Pract 43:182-186.
  225. Haddad A, Davis M, Lagman R. 2007. The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions. Support Care Cancer 15:251-257.
  226. Hall IA, Campbell KL, Chambers MD, et al. 1993. Effect of trimethoprim/sulfamethoxazole on thyroid function in dogs with pyoderma. J Am Vet Med Assoc 202:1959-1962.
  227. Halsey J. 2008. Current and future treatment modalities for Clostridium difficile-associated disease. Am J Health-Syst Pharm 65:705-715.
  228. Hannan PCT, Windsor GD, de Jong A, et al. 1997. Comparative susceptibilities of various animal-pathogenic mycoplasmas to fluoroquinolones. Antimicrobial Agents Chemother 41:2037-2040.
  229. Harari J, Besser TE, Gustafson SB, et al. 1993. Bacterial isolates from blood cultures of dogs undergoing surgery [comments]. Vet Surg 22:327-329.
  230. Harari J, Besser TE, Gustafson SB, et al. 1993. Bacterial isolates from blood cultures of dogs undergoing dentistry. Vet Surg 22:27-39.
  231. Harari J, Lincoln J. 1989. Pharmacologic features of clindamycin in dogs and cats. J Am Vet Med Assoc 195:124-125.
  232. Hare D. 1998. Microbial resistance to antimicrobial drugs. Can Vet J 39:329-331.
  233. Hariharan H, McPhee L, Heaney S, et al. 1995. Antimicrobial drug susceptibility of clinical isolates of Pseudomonas aeruginosa. Can Vet J 36:166-168.
  234. Harmoinen J, Mentula S, Heikkilä M, et al. 2004. Orally administered targeted recombinant β-lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance. Antimicrob Agents Chemother 48:75-79.
  235. Harrison MP, Moss SR, Featherstone A, et al. 1989. The disposition and metabolism of meropenem in laboratory animals and man. J Antimicrob Chemother 24:265-277.
  236. Harrus S, Kenny M, Miara L, et al. 2004. Comparison of simultaneous splenic sample PCR with blood sample PCR for diagnosis and treatment of experimental Ehrlichia canis infection. Antimicrob Agents Chemother 48:4488-4490.
  237. Harrus S, Waner T, Aizenberg I, et al. 1998. Therapeutic effect of doxycycline in experimental subclinical canine monocytic ehrlichiosis: evaluation of a 6-week course. J Clin Microbiol 36:2140-2142.
  238. Hartmann AD, Helps CR, Lappin MR, et al. 2008. Efficacy of pradofloxacin in cats with feline upper respiratory tract disease due to Chlamydophila felis or Mycoplasma infections. J Vet Intern Med 22:44-52.
  239. Harvey RG. 1987. Possible sulphadiazine-trimethoprim induced polyarthritis [letter]. Vet Rec 120:537-538.
  240. Harvey RG. 1996. Tylosin in the treatment of canine superficial pyoderma. Vet Rec 139:185-187.
  241. Harvey RG, Noble WC, Ferguson EA. 1993. A comparison of lincomycin hydrochloride and clindamycin hydrochloride in the treatment of superficial pyoderma in dogs. Vet Rec 132:351-353.
  242. Hawkins EC, Boothe DM, Guinn A, et al. 1998. Concentration of enrofloxacin and its active metabolite in alveolar macrophages and pulmonary epithelial lining fluid of dogs. J Vet Pharmacol Ther 21:18-23.
  243. Hayashi K, Takada K, Hirasawa M. 1998. Clinical and microbiological effects of controlled-release local delivery of minocycline on periodontitis in dogs. Am J Vet Res 59:464-467.
  244. Hayes JR, McIntosh AC, Qaiyumi S, et al. 2001. High frequency recovery of quinupristin-dalfopristin-resistant Enterococcus faecium isolates from the poultry production environment. J Clin Microbiol 39:2298-2299.
  245. Heilmann C, Jensen L, Jensen JS, et al. 2001. Treatment of resistant mycoplasma infection in immunocompromised patients with a new pleuromutilin antibiotic. J Infect 43:234-238.
  246. Heinen E. 1999. Comparative pharmacokinetics of enrofloxacin and difloxacin as well as their main metabolites in dogs. Compend Educ Pract Vet 21(Suppl):12-18.
  247. Heinen E. 2002. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J Vet Pharmacol Ther 25:1-5.
  248. Herrero IA, Fernández-Garayzábal JF, Moreno MA, et al. 2004. Dogs should be included in surveillance programs for vancomycin-resistant enterococci. J Clin Microbiol 42:1384-1385.
  249. Hildebrand H, Kempka G, Schluter G, et al. 1993. Chondrotoxicity of quinolones in vivo and in vitro. Arch Toxicol 67:411-415.
  250. Hirasawa M, Hayashi K, Takada K. 2000. Measurement of peptidase activity and evaluation of effectiveness of administration of minocycline for treatment of dogs with periodontitis. Am J Vet Res 61:1349-1352.
  251. Hirsh DC. 1995. Antimicrobial drugs: a strategy for rational use and the ramifications of misuse. Small Anim Med Digest 1:188-194.
  252. Hirsh DC, Jang SS. 1994. Antimicrobial susceptibility of selected infectious bacterial agents obtained from dogs. J Am Anim Hosp Assoc 30:487-494.
  253. Hirsh DC, Jang SS, Biberstein EL. 1990. Lack of supportive susceptibility data for use of ampicillin together with trimethoprim-sulfonamide as broad spectrum antimicrobial treatment of bacterial disease in dogs. J Am Vet Med Assoc 197:594-596.
  254. Hirt RA, Teinfalt M, Dederichs D, et al. 2003. The effect of orally administered marbofloxacin on the pharmacokinetics of theophylline. J Vet Med 50:246-250.
  255. Hogan RW. 1989. Therapeutics. JAMA 261:1652.
  256. Hooper DC. 2000. New uses for new and old quinolones and the challenge of resistance. Clin Infect Dis 30:243-254.
  257. Hooper DC. 2001. Mechanisms of action of antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1):S9-S15.
  258. Hooper DC, Wolfson JS. 1991. Drug therapy: fluoroquinolone antimicrobial agents. N Engl J Med 324:384.
  259. Horiuchi M, Kimura M, Tokumura M, et al. 2006. Absence of convulsive liability of doripenem, a new carbapenem antibiotic, in comparison with β-lactam antibiotics. Toxicology 222:114-124.
  260. Horspool LJ, van Laar P, van den Bos R, et al. 2004. Treatment of canine pyoderma with ibafloxacin and marbofloxacin—fluoroquinolones with different pharmacokinetic profiles. J Vet Pharmacol Ther 27:147-153.
  261. Horspool LJI, van Laar P, van den Bos R, et al. 2006. Clinical efficacy of two ibafloxacin formulations in the treatment of canine pyoderma. Vet Rec 158:236-237.
  262. Horvath C, Neuber A, Litschauer B. 2007. Pemphigus foliaceus-like drug reaction in a 3-month-old crossbreed dog treated for juvenile cellulitis. Vet Dermatol 18:353-359.
  263. Hoskins JD. 1993. Feline neonatal sepsis. Vet Clin North Am Small Anim Pract 23:91-100.
  264. Hostutler RA, Luria BJ, Johnson SE, et al. 2004. Antibiotic-responsive histiocytic ulcerative colitis in 9 dogs. J Vet Intern Med 18:499-504.
  265. Houston DM, Cochrane SM, Conlon P. 1989. Phenobarbital toxicity in dogs concurrently treated with chloramphenicol. Can Vet J 30:598.
  266. Howe LM, Boothe HW. 2006. Antimicrobial use in the surgical patient. Vet Clin Small Anim 36:1049-1060.
  267. Hunter RP, Lynch MJ, Ericson JF, et al. 1995. Pharmacokinetics, oral bioavailability and tissue distribution of azithromycin in cats. J Vet Pharmacol Ther 18:38-46.
  268. Ihrke PJ. 1996. Experiences with enrofloxacin in small animal dermatology. Compend Cont Educ Pract Vet 18:35-39.
  269. Ihrke PJ. 2002. Managing difficult cases of canine pyoderma. Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  270. Ihrke PJ, DeManuelle TC. 1999. German shepherd dog pyoderma: an overview and antimicrobial management. Compend Cont Educ Pract Vet 21:44-49.
  271. Ihrke PJ, Papich MG, Demanuelle TC. 1999. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol 10:193-204.
  272. Ingrey KT, Ren J, Prescott JF. 2003. A fluoroquinolone induces a novel mitogen-encoding bacteriophage in Streptococcus canis. Infect Immun 71:3028-3033.
  273. Intorre L, Mengozzi G, Maccheroni M, et al. 1995. Enrofloxacin theophylline interaction-influence of enrofloxacin on theophylline steady-state pharmacokinetics in the beagle dog. J Vet Pharmacol Ther 18:352-356.
  274. Ishak AM, Dowers KL, Cavanaugh MT, et al. 2008. Marbofloxacin for the treatment of experimentally induced Mycoplasma haemofelis infection in cats. J Vet Intern Med 22:288-292.
  275. Jackson MW, Panciera DL, Hartmann F. 1994. Administration of vancomycin for treatment of ascending bacterial cholangiohepatitis in a cat. J Am Vet Med Assoc 204:602-605.
  276. Jang SS, Breher JE, Dabaco LA, et al. 1997. Organisms isolated from dogs and cats with anaerobic infections and susceptibility to selected antimicrobial agents. J Am Vet Med Assoc 210:1610-1614.
  277. Jauernig S, Schweighauser A, Reist M, et al. 2001. The effects of doxycycline on nitric oxide and stromelysin production in dogs with cranial cruciate ligament rupture. Vet Surg 30:132-139.
  278. Johnson L. 2002. Diagnosis and treatment of a difficult respiratory case. Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  279. Jones RL, Godinho KS, Palmer GH. 1994. Clinical observations on the use of oral amoxicillin/clavulanate in the treatment of gingivitis in dogs and cats and anal sacculitis in dogs. Br Vet J 150:385-388.
  280. Jordan DG. 2001. Azithromycin. Small Anim/Exotics Compend Mar:242-247.
  281. Jung AC, Paauw DS. 1994. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch Intern Med 154:2402-2406.
  282. Kadlec K, Kehrenberg C, Schwarz S. 2005. Molecular basis of resistance to trimethoprim, chloramphenicol and sulphonamides in Bordetella bronchiseptica. J Antimicrob Chemother 56:485-490.
  283. Kather EJ, Marks SL, Kass PH. 2007. Determination of the in vitro susceptibility of feline Tritrichomonas foetus to 5 antimicrobial agents. J Vet Intern Med 21:966-970.
  284. Kaufman AC, Greene CE. 1993. Elevated alanine aminotransferase activity associated with tetracycline administration in a cat. J Am Vet Med Assoc 202:628-630.
  285. Kay-Mugford PA, Ramsey DT, Dubielzig RR, et al. 2001. Ocular effects of orally administered orbifloxacin in cats, pp 56. In Proceedings of the 32nd Annual Meeting American College of Veterinary Ophthalmology.
  286. Kay-Mugford PA, Weingarten AJ, Ngoh M, et al. 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet Ther 3:1-4.
  287. Kay-Mugford PA, Weingarten AJ, Ngoh M, et al. 2002. Determination of plasma and skin concentrations of orbifloxacin in dogs with clinically normal skin and dogs with pyoderma. Vet Ther 3:402-408.
  288. Kemming G, Messick JB, Mueller W, et al. 2004. Can we continue research in spenectomized dogs? Mycoplasma haemocanis: old problem—new insight. Eur Surg Res 36:198-205.
  289. Kernodle DS, Classen DC, Burke JP, et al. 1990. Failure of cephalosporins to prevent Staphylococcus aureus surgical wound infections. JAMA 263:961-966.
  290. Khan AA, Slifer TR, Araujo FG, Remington JS. 1999. Quinupristin-dalfopristin is active against Toxoplasma gondii. Antimicrob Agents Chemother 43:2043-2045.
  291. Kietzmann M. 1999. Overview of the pharmacokinetic properties of fluoroquinolones in domestic animals. Compend Cont Educ Pract Vet 21(Suppl, 12M):7-11.
  292. Kietzmann M. 1999. Overview of the pharmacokinetic properties of fluoroquinolones in companion animals. From the Proceedings of the Third International Veterinary Symposium on Baytril. Compend Cont Educ Pract Vet 21(Suppl):7-11.
  293. Kietzmann M, Mischke R, Albrecht N, et al. 1990. Vertraglichkeit und Pharmakokinetik von cephalaxin (Cefaseptin) beim Hund. Kleintierpraxis 35:390-398.
  294. Kietzmann M, Strothmann-Luerssen A, Grünau B, et al. 1992. Tolerance and pharmacokinetics of cephalexin in cats after oral administration. J Small Anim Pract 33:521-525.
  295. Kikuvi GM, Mitema ES, Buoro IB. 2001. The pharmacokinetics of a long-acting oxytetracycline formulation in healthy dogs and in dogs infected with Ehrlichia canis. Vet Res Commun 25:391-400.
  296. Kim D, Kordick D, Divers T, et al. 2006. In vitro susceptibilities of Leptospira spp. and Borrelia burgdorferi isolates to amoxicillin, tilmicosin, and enrofloxacin. J Vet Sci 7:355-359.
  297. Kiss G, Radványi SZ, Szigeti G. 1997. New combination for the therapy of canine otitis externa—I. Microbiology of otitis externa. J Small Anim Pract 38:51-56.
  298. Klein NC, Cunha BA. 2001. New uses of older antibiotics. Med Clin North Am 85:125-132.
  299. Klemens SP, Cynamon MH, Swenson CE, et al. 1990. Liposome-encapsulated gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother 34:967-970.
  300. Klesel N, Adam F, Limbert M, et al. 1992. RU 29 246, the active compound of the cephalosporin prodrug-ester HR 916 III. Pharmacokinetic properties and antibacterial activity in vivo. J Antibiot (Tokyo) 45:922-931.
  301. Kobayashi H. 1995. Biofilm disease: its clinical manifestation and therapeutic possibilities of macrolides. Am J Med 99(Suppl 6A):26-30.
  302. Kornder JD. 2002. Streptomycin revisited: molecular action in the microbial cell. Med Hypotheses 58:34-46.
  303. Kramer L, Grandi G, Leoni M, et al. 2008. Wolbachia and its influence on the pathology and immunology of Dirofilaria immitis infection. Vet Parasitol 158:191-195.
  304. Krol van Staaten MJ, Landheer JE, de Maat CE. 1990. Beware of the dog: meningitis in splenectomised woman. Neth J Med 36:301-303.
  305. Küng K, Hauser B, Wanner M. 1995. Effect of the interval between feeding and ampicillin absorption in dogs. J Small Anim Pract 36:65-68.
  306. Küng K, Riond JL, Wanner M. 1993. Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 16:462-468.
  307. Küng K, Wanner M. 1994. Bioavailability of different forms of amoxicillin administered orally to dogs. Vet Rec 135:552-554.
  308. Kunkle GA, Sundlof S, Keisling K. 1995. Adverse side effects of oral antibacterial therapy in dogs and cats: an epidemiologic study of pet owners’ observations. J Am Anim Hosp Assoc 31:46-55.
  309. Lacy MK, Nicolau DP, Nightingale CH, et al. 1998. The pharmacodynamics of aminoglycosides. Clin Infect Dis 27:23-27.
  310. Langer N. 2002. Cefixime. Compend Cont Educ Pract Vet 22:446-450.
  311. Lautzenhiser SJ, Fialkowski JP, Bjorling D, et al. 2001. In vitro antibacterial activity of enrofloxacin and ciprofloxacin in combination against Escherichia coli and staphylococcal clinical isolates from dogs. Res Vet Sci 70:239-241.
  312. Lavergne SN, Volkman EM, Make JE, et al. 2005. Evaluation of the clinical, immunologic, and biochemical effects of nitroso sulfamethoxazole administration to dogs: a pilot study. Toxicol 208:63-72.
  313. Lavy E, Goldstein R, Shem-Tov M, et al. 1995. Disposition kinetics of ampicillin administered intravenously and intraosseously to canine puppies. J Vet Pharmacol Ther 18:379-381.
  314. Lavy E, Ziv G, Aroch I, et al. 1995. Clinical pharmacologic aspects of cefixime in dogs. Am J Vet Res 56:633-638.
  315. Lavy E, Ziv G, Shem-Tov M, et al. 1995. Minimal inhibitory concentrations for canine isolates and oral absorption of roxithromycin in fed and fasted dogs. J Vet Pharmacol Ther 18:382-384.
  316. Lavy E, Ziv G, Shem-Tov, et al. 1999. Pharmacokinetics of clindamycin HCl administered intravenously, intramuscularly and subcutaneously to dogs. J Vet Pharmacol Ther 22:261-265.
  317. LeBel M. 1998. Introduction: International Society for Antiinfective Pharmacology (ISAP) Symposium on Pharmacodynamics of Antimicrobials. Clin Infect Dis 27:9.
  318. Ledbetter EC, Hendricks LM, Riis RC, et al. 2007. In vitro fluoroquinolone susceptibility of Pseudomonas aeruginosa from dogs with ulcerative keratitis. Am J Vet Res 68:638-642.
  319. Lee JS, Cho YS, Chang MH, et al. 2003. Synthesis and in vitro activity of novel isoxazolyl tetrahydropyrinyl oxazolidinone antibacterial agents. Bioorg Med Chem Left 13:4117-4120.
  320. Leemans J, Kirschvink N, Bernaerts F, et al. 2010. Effects of doxycycline on bronchial inflammation and hyperresponsiveness and on protease activity in a feline model of acute asthma. Proceedings ACVIM Forum, June 9-12, Anaheim, CA.
  321. Lefebvre HP, Schneider M, Dupouy V, et al. 1998. Effect of experimental renal impairment on disposition of marbofloxacin and its metabolites in the dog. J Vet Pharmacol Ther 21:453-461.
  322. Lenart J, Andersen AA, Rokey DD. 2001. Growth and development of tetracycline-resistant Chlamydia suis. Antimicrob Agents Chemother 45:2198-2203.
  323. Leonard FC, Markey BK. 2008. Methicillin-resistant Staphylococcus aureus in animals: a review, Vet J 175:27-36.
  324. Light RW, O’Hara VS, Moritz TE. 1990. Intrapleural tetracycline for the prevention of recurrent spontaneous pneumothorax. Results of a Department of Veterans Affairs Cooperative Study. JAMA 264:2224-2230.
  325. Lim JH, Park BK, Yun HI. 2006. Pharmacokinetic/pharmacodynamic modelling of roxithromycin for the inhibitory effect of tumour necrosis factor-alpha and interleukin-6 production in dogs. J Vet Med A 53:394-498.
  326. Lipman J, Allworth A, Wallis SC. 2000. Cerebrospinal fluid penetration of high doses of intravenous ciprofloxacin in meningitis. Clin Infect Dis 31:1131-1133.
  327. Lipsitch M, Samore MH. 2002. Antimicrobial use and antimicrobial resistance: a population perspective. Emerg Infect Dis 8:347-354.
  328. Lipsky BA, Baker CA. 1999. Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis 28:352-364.
  329. Lister A, Moss S, Honnery M, et al. 2007. Clinical efficacy and palatability of pradofloxacin 2.5% oral suspension for the treatment of bacterial lower urinary tract infection in cats. J Vet Intern Med 21:990-995.
  330. Littlewood JD, Lakhani KH, Paterson S, et al. 1999. Clindamycin hydrochloride and clavulanate-amoxicillin in the treatment of canine superficial pyoderma. Vet Rec 144:662-665.
  331. Liu CX, Wang JR, Lu YL. 1990. Pharmacokinetics of sulbactam and ampicillin in mice and dogs. Acta Pharm Sinica 25:406-411.
  332. Livermore DM, James D, Reacher M, et al. 2002. Trends in fluoroquinolones (Ciprofloxacin) resistance in Enterobacteriaceae from bacteremias, England and Wales, 1990-1999. Emerg Infect Dis 8:473-478.
  333. Lloyd DH, Carlotti DN, Koch HJ, et al. 1997. Treatment of canine pyoderma with co-amoxyclav: a comparison of two dose rates. Vet Rec 141:439-441.
  334. Lode H, Borner K, Koeppe P. 1998. Pharmacodynamics of fluoroquinolones. Clin Infect Dis 27:33-39.
  335. Lorian V. 1998. Antibiotics in animal feed. ASM News 64:311.
  336. Lupu M, McCune JS, Kuhr CD, et al. 2006. Pharmacokinetics of oral mycophenolate mofetil in dog: bioavailability studies and the impact of antibiotic therapy. Biol Blood Marrow Transplant 12:1342-1354.
  337. MacGregor RR, Graziani AL. 1997. Oral administration of antibiotics: a rational alternative to the parenteral route. Clin Infect Dis 24:457-467.
  338. Mahmood I. 1998. Interspecies scaling of renally secreted drugs. Life Sci 63:2365-2371.
  339. Malik R, Hunt GB, Goldsmid SE, et al. 1994. Diagnosis and treatment of pyogranulomatous panniculitis due to Mycobacterium smegmatis in cats. J Small Anim Pract 35:524-530.
  340. Mandsager RE, Clarke CR, Shawley RV, et al. 1995. Effects of chloramphenicol on infusion pharmacokinetics of propofol in Greyhounds. Am J Vet Res 56:95-99.
  341. Mansfield PD. 1990. Ototoxicity in dogs and cats. Compend Cont Educ Pract Vet 12:331-337.
  342. Marcellin-Little DJ, Papich MG, Richardson DC, et al. 1996. Pharmacokinetic model for cefazolin distribution during total hip arthroplasty in dogs. Am J Vet Res 57:720-723.
  343. Marchese A, Bozzolasco M, Gualco L, et al 2003. Effect of fosfomycin alone and in combination with N-acetylcysteine on E. coli biofilms. Int J Antimicrob Agents 22(suppl 2):95-100.
  344. Marchese A, Gualco L, Debbia EA, et al. 2003. In vitro activity of fosfomycin against gram-negative urinary pathogens and the biological cost of fosfomycin resistance. Int J Antimicrob Agents 22(suppl 2):53-59.
  345. Marco-Algarra J, Honrubia V. 1991. Comparative study of the effect of gentamicin on the vestibulo-ocular and visual vestibulo-ocular reflexes in the cat. Acta Otolaryngol Stockh 111:162-168.
  346. Marier JF, Beaudry F, Ducharme MP, et al. 2001. A pharmacokinetic study of amoxicillin in febrile beagle dogs following repeated administrations of endotoxin. J Vet Pharmacol Ther 24:379-383.
  347. Masters PA, O’Bryan TA, Zurlo J, et al. 2003. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 163:402-410.
  348. Matousek JL, Campbell KL. 2002. A review of cutaneous manifestations of idiosyncratic adverse drug reactions. Vet Med 97:899-910.
  349. Matsubayashi K, Shintani Y, Yoshioka M. 1992. Metabolic disposition of DQ-2556, a new cephalosporin in rats, rabbits, dogs, and monkeys. Antimicrob Agents Chemother 36:966-972.
  350. Matsumoto S, Takahashi M, Kitadai N, et al. 1998. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin. J Vet Med Sci 60:1259-1261.
  351. Matsumoto S, Takahashi M, Yoshida M, et al. 1997. Absorption, distribution and excretion of orbifloxacin in dogs and cats. J Jpn Vet Med Assoc 50:470-474.
  352. Mattie H, van Dokkum AM, Brus-Weijer L, et al. 1990. Antibacterial activity of four cephalosporins in an experimental infection in relation to in vitro effect and pharmacokinetics. J Infect Dis 162:717-722.
  353. Maxey BW. 1980. Efficacy of tetracycline-novobiocin combination against canine upper respiratory infections. Vet Med Small Anim Clin 75:89-92.
  354. McCall JW, Genchi C, Kramer L, et al. 2008. Heartworm and Wolbachia: therapeutic implications. Vet Parasitol 158:204-214.
  355. 351a. McClure JC, Crothers ML, Schaefer JJ, et al. 2010. Efficacy of a doxycycline treatment regimen initiated during three different phases of experimental ehrlichiosis. Antimicrob Agents Chemother 54:5012-5020.
  356. McKay LW, Rose CS, Matousek JL, et al. 2007. Pseudomonas aeruginosa isolates with marbofloxacin, enrofloxacin and orbifloxacin (abstract). North American Veterinary Dermatology Forum, Apr 18-22, Lihue, Kauai, HI.
  357. McCormick GG, Weinberg E, Szot RJ, et al. 1985. Comparative ototoxicity of netilmicin, gentamicin, and tobramycin in cats. Toxicol Appl Pharmacol 77:479-489.
  358. McCullers JA, English BK, Novak R. 2000. Isolation and characterization of vancomycin-tolerant Streptococcus pneumoniae from the cerebrospinal fluid of a patient who developed recrudescent meningitis. J Infect Dis 181:369-373.
  359. McDonald LC, Rossiter S, Mackinson C, et al. 2001. Quinupristin-dalfopristin-resistant Enterococcus faecium on chicken and in human stool specimens. N Engl J Med 345:1155-1160.
  360. McEvoy GK. 1997. American hospital formulary service drug information 1997. American Society of Health System Pharmacists, Bethesda, MD.
  361. McEwan NA. 1992. Presumptive trimethoprim-sulphamethoxazole associated thrombocytopenia and anemia in a dog. J Small Anim Pract 33:27-29.
  362. McGrotty YL, Knottenbelt CM. 2002. Oesophageal stricture in a cat due to oral administration of tetracyclines. J Small Anim Pract 43:221-223.
  363. McKellar QA. 1996. Clinical relevance of the pharmacologic properties of fluoroquinolones. From the Proceedings of the Second International Veterinary Symposium on Fluoroquinolones. Compend Contin Educ Pract Vet 18(Suppl):14-21.
  364. McKinnon PS, Davis SL. 2004. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases, Eur J Clin Microbiol Infect Dis 23:271-288.
  365. Mealey KL, Boothe DM. 1994. Nephrotoxicosis associated with topical administration of gentamicin in a cat. J Am Vet Med Assoc 12:1919-1921.
  366. Medleau L, Shanley KJ, Rakich PM. 1990. Trimethoprim-sulfonamide–associated drug eruptions in dogs. J Am Anim Hosp Assoc 26:305-311.
  367. Meinen JB, McClure JT, Rosin E. 1995. Pharmacokinetics of enrofloxacin in clinically normal dogs and mice and drug pharmacodynamics in neutropenic mice with Escherichia coli and staphylococcal infections. Am J Vet Res 56:1219-1224.
  368. Melendez LD, Twedt DC, Wright M. 2000. Suspected doxycycline-induced esophagitis with esophageal stricture formation in three cats. Feline Pract 28:10-12.
  369. Menozzi A, Pozzoli C, Poli E, et al. 2005. Effect of the macrolide antibacterial drug, tylosin, on TNSB-induced colitis in the rat. Pharmacology 74:135-142.
  370. Merchant SR, Neer TM, Tedford BL, et al. 1993. Ototoxicity assessment of a chlorhexidine otic preparation in dogs. Prog Vet Neurol 4:72-75.
  371. Messias A, Gekeler F, Wegener A, et al. 2008. Retinal safety of a new fluoroquinolone, pradofloxacin, in cats: assessment with electroretinography. Doc Ophthalmol 116:177-191.
  372. Messinger LM, Beale KM. 1993. A blinded comparison of the efficacy of daily and twice daily trimethoprim-sulfadiazine and daily sulfadimethoxine-ormetoprim therapy in the treatment of canine pyoderma. Vet Dermatol 4:13-18.
  373. Metchock B, Lonsway DR, Carter GP. 1991. Yersinia enterocolitica: a frequent seasonal stool isolate from children at an urban hospital in the southeast United States. J Clin Microbiol 29:2868-2869.
  374. Metchock B, McGowan JE. 1991. Evaluation of the Vitek GPS-TA card for laboratory detection of high-level gentamicin and streptomycin resistance in enterococci. J Clin Microbiol 29:2870-2872.
  375. Meunier D, Acar JF, Martel JL, et al. 2004. A seven-year survey of susceptibility to marbofloxacin of pathogenic strains isolated from pets. Int J Antimicrob Agents 24:592-598.
  376. Milanova A, Lashev L. 2002. Pharmacokinetics of oleandomycin in dogs after intravenous or oral administration alone and after pretreatment with metamizole or dexamethasone. Vet Res Commun 26:61-71.
  377. Modai J. 1996. Diffusion of 3-quarternary ammonium cephem antibiotics into cerebrospinal fluid of patients with bacterial meningitis. J Chemother 8:83-90.
  378. Moellering RC, Linden PK, Reinhardt J, et al. 1999. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 44:251-261.
  379. 374a. Monfrinotti A, Ambros L, Montoya L, et al. 2010. Chronokinetics of ceftazidime after intramuscular administration to dogs. Chronobiol Int 27:549-559.
  380. Monlouis JD, DeJong A, Limet A, et al. 1997. Plasma pharmacokinetics and urine concentrations of enrofloxacin after oral administration of enrofloxacin in dogs. J Vet Pharmacol Ther 20(Suppl 1):61-63.
  381. Montesissa C, Villa R, Anfossi P, et al. 2003. Pharmacodynamics and pharmacokinetics of cefoperazone and cefamandole in dogs following single dose intravenous and intramuscular administration. Vet J 166:170-176.
  382. Moon YSK, Chung KC, Gill MA. 1997. Pharmacokinetics of neoplasm in animals, healthy volunteers, and patients. Clin Infect Dis 24(Suppl):S249-S255.
  383. Moore KW, Trepanier LA, Lautzenhiser SJ, et al. 2000. Pharmacokinetics of ceftazidime in dogs following subcutaneous administration and continuous infusion and the association with in vitro susceptibility of Pseudomonas aeruginosa. Am J Vet Res 61:1204-1208.
  384. Morley PS, Apley MD, Besser TE, et al. 2005. Antimicrobial drug use in veterinary medicine. J Vet Intern Med 19:617-629.
  385. Morresey PR. 2001. Therapeutic intervention strategies in endotoxemia. Compendium 23:925-931.
  386. Mueller RS, Fieseler KV, Bettenay SV, et al. 2002. Influence of long-term treatment with tetracycline and niacinamide on antibody production in dogs with discoid lupus erythematosus. Am J Vet Res 63:491-494.
  387. Mueller RS, Rosychuk RAW, Jonas LD. 2003. A retrospective study regarding the treatment of lupoid onychodystrophy in 30 dogs and literature review. J Am Anim Hosp Assoc 39:139-150.
  388. Mueller RS, Stephan R. 2007. Prodofloxacin in the treatment of canine deep pyoderma: a multicentred, blinded, randomized parallel trial. Vet Dermatol 18:144-151.
  389. Muir P, Gruffydd-Jones TJ, Cripps PJ, et al. 1996. Breath hydrogen excretion by healthy cats after oral administration of oxytetracycline and metronidazole. Vet Rec 138:635-639.
  390. Murray BE. 1997. Vancomycin-resistant enterococci. Am J Med 102:284-293.
  391. National Committee on Clinical Laboratory Standards [NCCLS]. 1999. Performance standards for antimicrobial disk and dilution susceptibility tests for bacterial isolated from animals; approved Standard, NCCLS document #M31-A. NCCLS, Wayne, PA.
  392. Neer TM, Eddlestone SM, Gaunt SD, et al. 1999. Efficacy of enrofloxacin for the treatment of experimentally induced Ehrlichia canis infection. J Vet Intern Med 13:501-504.
  393. Neu HC. 1990. Third generation cephalosporins: safety profiles after 10 years of clinical use. J Clin Pharmacol 30:396-403.
  394. Neu HC. 1992. New macrolide antibiotics: azithromycin and clarithromycin. Ann Intern Med 116:517-519.
  395. Nielsen D, Walser C, Kodan G, et al. 2000. Effects of treatment with clindamycin hydrochloride on progression of canine periodontal disease after ultrasonic scaling. Vet Ther 1:150-158.
  396. Nielsen OS, Møller NF, Maigaard S, et al. 1981. Nitroimidazoles in the canine prostates, vagina and urethra. Prostate 2:71-78.
  397. Norden CW, Shinners E, Niederriter K. 1986. Clindamycin treatment of experimental chronic osteomyelitis due to Staphylococcus aureus. J Infect Dis 153:956-959.
  398. Normand EH, Gibson NR, Taylor DJ, et al. 2000. Trends of antimicrobial resistance in bacterial isolates from a small animal referral hospital. Vet Rec 146:151-155.
  399. Nossaman BC, Amouzadeh HR, Sangiah S. 1990. Effects of chloramphenicol, cimetidine and phenobarbital on and tolerance to xylazine-ketamine anesthesia in dogs. Vet Hum Toxicol 32:216-219.
  400. Novotny MJ, Shaw DH. 1991. Effect of enrofloxacin on digoxin clearance and steady-state serum concentrations in dogs. Can J Vet Res 55:113-116.
  401. Nuttall TJ. 1998. Use of ticarcillin in the management of canine otitis externa complicated by Pseudomonas aeruginosa. J Small Anim Pract 39:165-168.
  402. Nuttall TJ, Malham T. 2004. Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. J Small Anim Pract 45:357-361.
  403. Nyirjesy P, Sobel JD, Weitz V, et al. 1998. Difficult to treat trichomoniasis: results with paromomycin cream. Clin Infect Dis 26:986-988.
  404. Oakes JA, Seifert SA. 2008. American Association of Poison Control Centers database characterization of human tilmicosin exposures, 2001-2005. J Med Toxicol 4:225-231.
  405. Odensvik K, Grave K, Greko C. 2001. Antibacterial drugs prescribed for dogs and cats in Sweden and Norway 1990-1998. Acta Vet Scand 42:189-198.
  406. Odensvik K, Greko C. 1998. Antibacterials for animals—an update. Swed Vet J 50:313-316.
  407. Ogeer-Gyles J, Mathews KA, Boerlin P. 2004. Tracing the origin of multi-drug resistant (MDR) Escherichia coli infections from urinary catheters in ICU canine patients [abstract]. Veterinary Emergency Critical Care Society, San Diego.
  408. Ogeer-Gyles J, Mathews KA, Prescott J, et al. 2004. Development of antibiotic resistance in Escherichia coli from dogs in the intensive care unit with increased duration of stay [abstract]. Veterinary Emergency Critical Care Society, San Diego.
  409. Ogeer-Gyles J, Mathews K, Weese JC, et al. 2006. Evaluation of catheter-associated urinary tract infections and multi-drug-resistant Escherichia coli isolates from the urine of dogs with indwelling urinary catheters. J Am Vet Med Assoc 229:1584-1590.
  410. Ogino T, Mizuno Y, Ogata T, et al. 2005. Pharmacokinetic interactions of flunixin meglumine and enrofloxacin in dogs. Am J Vet Res 66:1209-1213.
  411. Okeke IN, Edelman R. 2001. Dissemination of antibiotic-resistant bacteria across geographic borders. Clin Infect Dis 33:364-369.
  412. Olson EJ, Morales SC, McVey AS, et al. 2005. Putative metronidazole neurotoxicosis in a cat. Vet Pathol 42:665-669.
  413. Oluoch AO, Kim CH, Weisiger RM, et al. 2001. Nonenteric Escherichia coli isolates from dogs: 674 cases (1990-1998). J Am Vet Med Assoc 218:381-384.
  414. Orsini JA, Perkons S. 1994. New beta-lactam antibiotics in critical care medicine. Compend Cont Educ Pract Vet 16:183-186.
  415. Osborne CA. 2002. Recurrent bacterial urinary tract infection in a cat with chronic renal failure. Symposium on Cutting-Edge Clinical Cases, Western Veterinary Conference, Feb 13.
  416. Ossiprandi MC, Bottarelli E, Cattabiani F, et al. 2008. Susceptibility to vancomycin and other antibiotics of 165 Enterococcus strains isolated from dogs in Italy. Comp Immunol Microbiol Infect Dis 31:1-9.
  417. Ostro MJ, Cullis PR. 1989. Use of liposomes as injectable-drug delivery systems. Am J Hosp Pharm 46:1576-1587.
  418. Owen WM, Sturgess CP, Harbour DA, et al. 2003. Efficacy of azithromycin for the treatment of feline chlamydophilosis. J Feline Med Surg 5:305-311.
  419. Page SW. 1991. Chloramphenicol: 1. Hazards of use and the current regulatory environment. Aust Vet J 68:1-2.
  420. Pak SI, Han HR, Shimizu A. 1999. Characterization of methicillin-resistant Staphylococcus aureus isolated from dogs in Korea. J Vet Med Sci 61:1013-1018.
  421. Palmeiro BS, Morris DO, Goldschmidt MH, et al. Cutaneous reactive histiocytosis in dogs: a retrospective evaluation of 32 cases. North American Veterinary Dermatology Forum, Apr 18-22, Lihue, Kauai, HI.
  422. 416a. Pantozzi FL, Moredo FA, Vigo GB, et al. 2010. Antimicrobial resistance in indicator and zoonotic bacteria isolated from domestic animals in Argentina. Rev Argent Microbiol 42:49-52.
  423. Papich MG. 1999. Comparison of fluoroquinolone antibacterials. Proc Am Coll Vet Intern Med 17:53-55.
  424. Papich, MG. 1999. Florfenicol pharmacokinetics in dogs and cats (Abstract No. 235), 17th Annual Veterinary Medical Forum, American College of Veterinary Internal Medicine, June 10-13, Chicago.
  425. Papp JR, Muckle CA. 1991. Antimicrobial susceptibility testing of veterinary clinical isolates with the Sceptor System. J Clin Microbiol 29:1249-1251.
  426. Paradis M, Lemay S, Scott DW, et al. 1990. Efficacy of enrofloxacin in the treatment of canine bacterial pyodermas. Vet Dermatol 1:123-127.
  427. Paradis M, Abbey L, Baker B, et al. 2001. Evaluation of the clinical efficacy of marbofloxacin (Zeniquin) tablets for the treatment of canine pyoderma: an open clinical trial. Vet Dermatol 12:163-169.
  428. Parpia SH, Nix DE, Hejmanowski LG, et al. 1989. Sucralfate reduces the gastrointestinal absorption of norfloxacin. Antimicrob Agents Chemother 33:99-102.
  429. Pascoe PJ, Ilkiw JE, Kass PH, et al. 1996. Case control study of the association of intraoperative administration of nafcillin and acute postoperative development of azotemia. J Am Vet Med Assoc 208:1043-1047.
  430. Passmore CA, Sherington J, Stegemann MR. 2007. Efficacy and safety of cefovecin (Convenia) for the treatment of urinary tract infections in dogs. J Small Anim Pract 48:139-144.
  431. Petersen SW, Rosin E. 1993. In vitro antibacterial activity of cefoxitin and cefotetan and pharmacokinetics in dogs. Am J Vet Res 54:1496-1499.
  432. Pfizer. 2004. Simplicef package insert. Pfizer, New York.
  433. Pfizer Animal Health. 2008. Convenia prescribing information. Pfizer Animal Health, New York.
  434. Pfizer Animal Health. 2008. Draxxin prescribing information. Pfizer Animal Health, New York.
  435. Pickrell JA, Oehme FW, Cash WC. 1993. Ototoxicity in dogs and cats. Semin Vet Med Surg Small Anim 8:42-49.
  436. Piddock LJV. 1993. Newer fluoroquinolones and gram-positive bacteria. AMS News 59:603-608.
  437. Piddock LJ, Hart CA, Johnston AM, et al. 1998. Review of the literature on antibiotic resistance in foodborne pathogens. ASM News 64:311-312.
  438. Pirro F, Edingloh M, Schmeer N. 1999. Bactericidal and inhibitory activity of enrofloxacin and other fluoroquinolones in small animal pathogens. Compend Cont Educ Pract Vet 21(Suppl):19-25.
  439. Pohlenz-Zertuche HO, Brown MP, Gronwall R, et al. 1992. Serum and skin concentrations after multiple-dose oral administration of trimethoprim-sulfadiazine in dogs. Am J Vet Res 53:1273-1276.
  440. Prados AP, Ambros L, Montoya L, et al. 2007. Chronopharmacological study of cephalexin in dogs. Chronobiol Int 23:161-170.
  441. Prados AP, Kreil V, Albarellos G, et al. 2007. Metoclopramide modifies oral cephalexin pharmacokinetics in dogs. J Vet Pharmacol Ther 30:127-131.
  442. Prescott JF. 1998. Bacterial resistance. Can Vet J 39:378.
  443. Prescott JF. 2000. Miscellaneous antibiotics, pp 339-366. In Prescott JF, Baggot JD, Walker RD (eds): Antimicrobial therapy in veterinary medicine, ed 3. WB Saunders, Philadelphia.
  444. Prescott JF, Hanna B, Reid-Smith R, et al. 2002. Antimicrobial drug use and resistance in dogs. Can Vet J 43:107-116.
  445. Prescott JF, Yielding KM. 1990. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin. Can J Vet Res 54:195-197.
  446. Pressel MA, Fox LE, Apley MD, et al. 2005. Vancomycin for multi-drug resistant Enterococcus faecium cholangioheptatitis in a cat. J Feline Med Surg 7:317-321.
  447. Pfizer. 2004. Simplicef product information. Pfizer, New York.
  448. Rantala M, Hölsö K, Lillas A, et al. 2004. Survey of condition-based prescribing of antimicrobial drugs for dogs at a veterinary teaching hospital. Vet Rec 155:259-262.
  449. Rantala M, Lahti E, Kuhalampil J, et al. 2004. Antimicrobial resistance in Staphylococcus spp., Escherichia coli and Enterococcus spp. in dogs given antibiotics for chronic dermatological disorders, compared with non-treated control dogs. Acta Vet Scand 45:37-45.
  450. Rees CA, Boothe DM. 2004. Evaluation of the effect of cephalexin and enrofloxacin on clinical laboratory measurements of urine glucose in dogs. J Am Vet Med Assoc 224:1455-1458.
  451. Regnier A, Concordet D, Schneider M, et al. 2003. Population pharmacokinetics of marbofloxacin in aqueous humor after intravenous administration in dogs. Am J Vet Res 64:889-893.
  452. Restrepo CR, Ihrke SD, White SD, et al. 2007. The concentration time course of pradofloxacin in the skin of dogs with and without pyoderma. Vet Dermatol 18:12-14.
  453. 446a. Restrepo CR, Ihrke PJ, White SD, et al. 2010. Evaluation of the clinical efficacy of pradofloxacin tablets for the treatment of canine pyoderma. J Am Anim Hosp Assoc 46:301-311.
  454. Ribeiro MG, Salerno T, de Mattos-Guaraldi AL, et al. 2008. Nocardiosis: an overview and additional report of 28 cases in cattle and dogs. Rev Inst Med Trop S Paulo 50:177-185.
  455. Richez P, Monlouis JD, Dellac B, et al. 1997. Validation of a therapeutic regimen for enrofloxacin in cats on the basis of pharmacokinetic data. J Vet Pharmacol Ther 20:152-153.
  456. Riond JL, Riviere JE. 1990. Allometric analysis of doxycycline pharmacokinetic parameters. J Vet Pharmacol Ther 13:404-407.
  457. Riond JL, Vaden SL, Riviere JE. 1990. Comparative pharmacokinetics of doxycycline in cats and dogs. J Vet Pharmacol Ther 13:415-424.
  458. Riviere JE. 1991. Handbook of comparative pharmacokinetics and residues of veterinary antimicrobials. CRC Press, Boca Raton, FL.
  459. Riviere JE. 1999. Interspecies extrapolations, pp 296-307. In Riviere JE (ed): Comparative pharmacokinetics. Principles, techniques, and applications, ed 1. Iowa State University Press, Ames, IA.
  460. Riviere JE, Martín-Jiménez T, Sundlof SF, et al. 1997. Interspecies allometric analysis of the comparative pharmacokinetics of 44 drugs across veterinary and laboratory animal species. J Vet Pharmacol Ther 20:453-463.
  461. Roberts MC. 2003. Tetracycline therapy: update. Clin Infect Dis 36:462-467.
  462. Rodrigues J, Poeta P, Martins A, et al. 2002. The importance of pets as reservoirs of resistant Enterococcus strains, with special reference to vancomycin. J Vet Med B Infect Dis Vet Public Health 49:278-280.
  463. Rosenkrantz WS. 2004. Pemphigus: current therapy. Vet Dermatol 15:90-98.
  464. Rosin E. 1990. Empirical selection of antibiotics in small animal surgery. Compend Cont Educ Pract Vet 12:231-232.
  465. Rosin E, Ebert S, Uphoff TS, et al. 1989. Penetration of antibiotics into the surgical wound in a canine model. Antimicrob Agents Chemother 33:700-704.
  466. Rosin E, Uphoff TS, Schultz-Darken NJ. 1993. Cefazolin antibacterial activity and concentrations in serum and the surgical wound in dogs. Am J Vet Res 54:1317-1321.
  467. Rothstein E, Scott DW, Riis RC. 1997. Tetracycline and niacinamide for the treatment of sterile pyogranuloma/granuloma syndrome in a dog. J Am Anim Hosp Assoc 33:540-543.
  468. Rotschafer JC, Wright DH, Brown GH. 1999. Gram-positive infections: pharmacy issues and strategy for quinupristin/dalfopristin. Diagn Microbial Infect Dis 33:95-99.
  469. Rowland PH, Center SA, Dougherty SA. 1992. Presumptive trimethoprim-sulfadiazine B-related hepatotoxicosis in a dog. J Am Vet Med Assoc 200:348-350.
  470. Roy J, Messier S, Labrecque O, et al. 2007. Clinical and in vitro efficacy of amoxicillin against bacteria associated with feline skin wounds and abscesses. Can Vet J 48:607-611.
  471. Rubenstein E, Meissel D, Klein E, et al. 1988. Effect of pancreatitis on moxalactam excretion in pancreatic fluids of dogs and man. World J Surg 12:411-414.
  472. Rubin J, Walker RD, Blickenstaff K, et al. 2008. Antimicrobial resistance and genetic characterization of fluoroquinolone resistance of Pseudomonas aeruginosa isolated from canine infections. Vet Microbiol 131:164-172.
  473. Rubin SI, Toolan L, Halperin ML. 1998. Trimethoprim-induced exacerbation of hyperkalemia in a dog with hypoadrenocorticism. J Vet Intern Med 12:186-188.
  474. Ruch-Gallie RA, Veir JK, Spindel ME, et al. 2008. Efficacy of amoxicillin and azithromycin for the empirical treatment of shelter cats with suspected bacterial upper respiratory infections. J Feline Med Surg 10:542-550.
  475. Russell NJ, Tyrrell D, Irwin PJ, et al. 2008. Pneumatosis coli in a dog. J Am Anim Hosp Assoc 44:32-35.
  476. Rutgers HC, Stepien RL, Elwood CM, et al. 1994. Enrofloxacin treatment of gram-negative infections. Vet Rec 135:357-359.
  477. Rybníček J, Hill PB. 2007. Suspected polymyxin B-induced pemphigus vulgaris in a dog. Vet Dermatol 18:165-170.
  478. Sabnis S. 1999. Factors influencing the bioavailability of peroral formulations of drugs for dogs. Vet Res Commun 23:425-447.
  479. Saint Omer VV. 1978. Efficacy and toxicity of furazolidone in veterinary medicine (a review). Vet Med Small Anim Clin 73:1125-1128.
  480. Salmon SA, Watts JL, Yancey RJ. 1996. In vitro activity of ceftiofur and its primary metabolite desfuroylceftiofur against organisms of veterinary importance. J Vet Diagn Invest 8:332-336.
  481. Sanchez S, McCrackin Stevenson MA, Hudson CR, et al. 2002. Characterization of multidrug-resistant Escherichia coli isolates associated with nosocomial infections in dogs. J Clin Microbiol 40:3586-3595.
  482. Sanders JE, Yeary RA, Fenner WR, et al. 1979. Interaction of phenytoin with chloramphenicol or pentobarbital in the dog. J Am Vet Med Assoc 175:177-180.
  483. Saravolatz LD, Leggett J. 2003. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 37:1210-1215.
  484. Sarkiala E. 1992. Penetration of tinidazole into the gingival crevicular fluid in dogs. Res Vet Sci 52:391-393.
  485. Sarkiala E, Harvey C. 1993. Systemic antimicrobials in the treatment of periodontitis in dogs. Semin Vet Med Surg Small Anim 8:197-203.
  486. Sarkiala E, Järvinen A, Valttila S, et al. 1991. Pharmacokinetics of tinidazole in dogs and cats. J Vet Pharmacol Ther 14:257-262.
  487. Sarkiala EM. 1993. Treatment of periodontitis in dogs with tinidazole. J Small Anim Pract 34:90-94.
  488. Sarkiala-Kessel EM, Jarvinen A, Nokelainen M, et al. 1996. Concentrations of tinidazole in gingival crevicular fluid and plasma in dogs after multiple dose administration. J Vet Pharmacol Ther 19:171-175.
  489. Sato R, Soeta S, Syuto B, et al. 2002. Urinary excretion of N-acetyl-β-D-glucosaminidase and its isoenzymes in cats with urinary disease. J Vet Med Sci 64:367-371.
  490. Schaefer JJ, Kahn J, Needham GR, et al. 2008. Antibiotic clearance of Ehrlichia canis from dogs infected by intravenous inoculation of carrier blood. Ann NY Acad Sci 1149:263-269.
  491. Schaefer JJ, Needham GR, Bremer WG, et al. 2007. Tick acquisition of Ehrlichia canis from dogs treated with doxycycline hyclate. Antimicrob Agents Chemother 51:2294-2296.
  492. Scheld WM. 2003. Maintaining fluoroquinolone class efficacy: review of influencing factors. Emerg Infect Dis 9:1-9.
  493. Schentag JJ, Meagher AK, Forrest A. 2003. Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: in vitro and animal models. Ann Pharmacother 37:1287-1298.
  494. Schentag JJ, Strenkoski-Nix LC, Nix DE, et al. 1998. Pharmacodynamic interactions of antibiotics alone and in combination. Clin Infect Dis 27:40-46.
  495. Schultz B, Hartmann K. 2007. Use of fluoroquinolones in cats [letter]. Vet Rec 160:32.
  496. Schwarz S, Kehrenberg C, Doublet B, et al. 2004. Molecular basis of bacterial resistance to chloramphenicol and florfenicol. FEMS Microbiol Rev 28:519-542.
  497. Schwarz S, Noble W. 1999. Aspects of bacterial resistance to antimicrobials used in veterinary dermatological practice. Vet Dermatol 10:163-176.
  498. 490a. Scott B, Mortensen J, McKeever T, et al. 2010. Efficacy of tylosin tartrate on canine staphylococcus intermedius isolates in vitro. Vet Ther 11:E1-E7.
  499. Scott DW, Miller WH. 2008. Letter to the editor. Vet Dermatol 19:105.
  500. Scott DW, Miller WH, Cayatte SM, et al. 1994. Efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Can Vet J 35:617-621.
  501. Scott DW, Miller WH, Rothstein SE, et al. 1996. Further studies on efficacy of tylosin tablets for the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Can Vet J 37:617-618.
  502. Scott DW, Miller WH, Wellington JR. 1993. The combination of ormetoprim and sulfadimethoxine in the treatment of pyoderma due to Staphylococcus intermedius infection in dogs. Canine Pract 18:29-33.
  503. Seelig DM, Whittemore JC, Lappin MR, et al. 2008. Goitrous hypothyroidism associated with treatment with trimethoprim-sulfamethoxazole in a young dog. J Am Vet Med Assoc 232:1181-1185.
  504. Seguin JC, Walker RD, Caron JP, et al. 1999. Methicillin-resistant Staphylococcus aureus outbreak in a veterinary teaching hospital: potential human-to-animal transmission. J Clin Microbiol 37:1459-1463.
  505. Seguin MA, Papich MG, Sigle KJ, et al. 2004. Pharmacokinetics of enrofloxacin in neonatal kittens. Am J Vet Res 65:350-356.
  506. 497a. Sekis I, Ramstead K, Rishniw M, et al. 2009. Single-dose pharmacokinetics and genotoxicity of metronidazole in cats. J Fel Med Surg 11:60-68.
  507. Seltzer E, Dorr MB, Goldstein BP, et al. 2003. Once-weekly dalbavancin versus standard-of-care antimicrobial regimens for treatment of skin and soft-tissue infections. Clin Infect Dis 37:1298-1303.
  508. Šeol B, Naglić T, Madić J, et al. 2002. In vitro antimicrobial susceptibility of 183 Pseudomonas aeruginosa strains isolated from dogs to selected antipseudomonal agents. J Vet Med B 49:188-192.
  509. Shaheen BW, Boothe DM, Oryzabal O, Smaha T. 2010. Antimicrobial resistance profiles and clonal relatedness of canine and feline Escherichia coli pathogens expressing multidrug resistance in the United States. J Vet Intern Med 24:323-330.
  510. Shaheen BW, Boothe DM, Oyarzabal O, et al. 2011. Evaluation of the contribution of gyrA mutation and efflux pumps to fluoroquinolone and multi drug resistance in canine and feline pathogenic Escherichia coli isolates from dogs and cats. Am J Vet Res 72:25-32.
  511. Shapiro ED. 2001. Doxycycline for tick bites—not for everyone. N Engl J Med 345:133-134.
  512. Shepard RM, Falkner FC. 1990. Pharmacokinetics of azithromycin in rats and dogs. J Antimicrob Chemother 25(Suppl A):49-60.
  513. Shiba KA, Saito A, Shimada J, et al. 1990. Renal handling of fleroxacin in rabbits, dogs, and humans. Antimicrob Agents Chemother 34:58-64.
  514. Sidhu MS, Oppegaard H, Devor TP, et al. 2007. Persistence of multidrug-resistant Staphylococcus haemolyticus in an animal veterinary teaching hospital clinic. Microb Drug Resist 13:271-280.
  515. Sidjabat HE, Hanson ND, Smith-Moland E, et al. 2007. Identification of plasmid-mediated extended-spectrum and AmpC β-lactamases in Enterobacter spp. isolated from dogs. J Med Microbiol 56:426-434.
  516. Sieber-Ruckstuhl NS, Sessions JK, Sanchez S, et al. 2007. Long-term cure of disseminated Mycobacterium avium infection in a cat. Vet Rec 160:131-132.
  517. Siefert HM, Domdey-Bette A, Henninger K, et al. 1999. Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. J Antimicrob Chemother 43(Suppl B):69-76.
  518. Silley P, Stephan B, Greife HA, et al. 2007. Comparative activity of pradofloxacin against anaerobic bacteria isolated from dogs and cats. J Antimicrob Chemother 60:999-1003.
  519. Six R, Cherni J, Chesebrough R, et al. 2008. Efficacy and safety of cefovecin in treating bacterial folliculitis, abscesses, or infected wounds in dogs. J Am Vet Med Assoc 233:433-439.
  520. Six R, Cleaver DM, Lindeman CJ, et al. 2009. Effectiveness and safety of cefovecin sodium, an extended-spectrum injectable cephalosporin, in the treatment of cats with abscesses and infected wounds. J Am Vet Med Assoc 234:81-87.
  521. Slatter JG, Adams LA, Bush EC, et al. 2002. Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907-924.
  522. Smith IM, Mackie A, Lida J. 1991. Effect of giving enrofloxacin in the diet to pigs experimentally infected with Actinobacillus pleuropneumoniae. Vet Rec 129:25.
  523. Snyder LA, Birkenheuer AJ, Neel J, et al. 2006. Drug-induced haemolytic anemia in a cat. Vet Clin Pathol 35:366.
  524. Sorenmo K, Duda L, Barber L, et al. 2000. Canine hemangiosarcoma treated with standard chemotherapy and minocycline. J Vet Intern Med 14:395-398.
  525. Sparks TA, Kemp DT, Wooley RE, et al. 1994. Antimicrobial effect of combinations of EDTA-Tris and amikacin or neomycin on the microorganisms associated with otitis externa in dogs. Vet Res Commun 18:241-249.
  526. Speer BS, Shoemaker NB, Salyers AA. 1992. Bacterial resistance to tetracycline: mechanisms, transfer and clinical significance. Clin Microbiol Rev 5:387-399.
  527. Spindel ME, Veir JK, Radecki SV, et al. 2008. Evaluation of pradofloxacin for the treatment of feline rhinitis. J Feline Med Surg 10:472-479.
  528. Spreng M, Deleforge J, Thomas V, et al. 1995. Antibacterial activity of marbofloxacin—a new fluoroquinolone for veterinary use against canine and feline isolates. J Vet Pharmacol Ther 18:284-289.
  529. Stampley AR, Brown MP, Gronwall RR, et al. 1991. Serum concentrations of cefepime (BMY-28142), a broad-spectrum cephalosporin, in dogs. Cornell Vet 82:69-76.
  530. Stegemann MR, Coati N, Passmore CA, et al. 2007. Clinical efficacy and safety of cefovecin in the treatment of canine pyoderma and wound infections. J Small Anim Pract 48:378-386.
  531. Stegemann M, Heukamp U, Scheer M, et al. 1996. Kinetics of antibacterial activity after administration of enrofloxacin in dogs serum and skin: in vitro susceptibility of field isolates. Compend Cont Educ Pract Vet 18:30-34.
  532. Stegemann MR, Passmore CA, Sherington J, et al. 2006. Antimicrobial activity and spectrum of cefovecin, a new extended-spectrum cephalosporin, against pathogens collected from dogs and cats in Europe and North America. Antimicrob Agents Chemother 50:2286-2292.
  533. Stegemann MR, Sherington J, Blanchflower S. 2006. Pharmacokinetics and pharmacodynamics of cefovecin in dogs. J Vet Pharmacol Ther 29:501-511.
  534. Stegemann MR, Sherington J, Coati N, et al. 2006. Pharmacokinetics of cefovecin in cats. J Vet Pharmacol Ther 29:513-524.
  535. Stegemann MR, Sherington J, Passmore C. 2007. The efficacy and safety of cefovecin in the treatment of feline abscesses and infected wounds. J Small Anim Pract 48:683-689.
  536. Stein GE, Goldstein EJC. 2006. Fluoroquinolones and anaerobes. Clin Infect Dis 42:1598-1607.
  537. Stephan B, Greife HA, Pridmore A, et al. 2008. Activity of pradofloxacin against Porphyromonas and Prevotella spp. implicated in periodontal disease in dogs: susceptibility test data from a European multicenter study. Antimicrob Agents Chemother 52:2149-2155.
  538. Sternberg S. 1999. Antimicrobial resistance in bacteria from pets and humans. Acta Vet Scand 92(Suppl):37-50.
  539. Sterner KE. 1991. An overview of new guidelines on the use and dispensing of veterinary drugs. J Am Vet Med Assoc 198:825.
  540. Strain GM, Merchant SR, Neer TM, et al. 1995. Ototoxicity assessment of a gentamicin sulfate otic preparation in dogs. Am J Vet Res 56:532-537.
  541. Ström B, Linde-Forsberg C. 1993. Effects of ampicillin and trimethoprim-sulfamethoxazole on the vaginal bacterial flora of bitches. Am J Vet Res 54:891-896.
  542. Ström B, Schinnar R, Apter AJ, et al. 2003. Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics. N Eng J Med 349:1628-1635.
  543. Strube W, Thein P, Kretzdorn D, et al. 1989. Baypamun: new possibilities for the control of infectious diseases in domestic animals. Vet Med Rev 60:3-15.
  544. Studdert VP, Hughes KL. 1992. Treatment of opportunistic mycobacterial infections with enrofloxacin in cats. J Am Vet Med Assoc 201:1388-1390.
  545. 535a. Suchodolski JS, Dowd SE, Westermarck E, et al. 2009. The effect of the macrolide antibiotic tylosin on microbial diversity in the canine small intestine as demonstrated by massive 16S rRNA gene sequencing. BMC Microbiol 9:210.
  546. Sugie M, Asakura E, Zhao YL, et al. 2004. Possible involvement of the drug transporters P glycoprotein and multidrug resistance-associated protein Mrp2 in disposition of azithromycin. Antimicrob Agents Chemother 48:809-814.
  547. Sullivan PS, Arrington K, West R, et al. 1992. Thrombocytopenia associated with administration of trimethoprim/sulfadiazine in a dog. J Am Vet Med Assoc 201:1741-1744.
  548. Sumano H, Gutierrez L, Ocampo L. 2004. Pharmacokinetics and clinical efficacy of cefotaxime for the treatment of septicaemia in dogs. Acta Vet Hung 52:85-95.
  549. Swalec-Tobias KM, Schneider RK, Besser TE. 1996. Use of antimicrobial-impregnated polymethyl methacrylate. J Am Vet Med Assoc 208:841-845.
  550. Swenson CE, Stewart KA, Hammett JL, et al. 1990. Pharmacokinetics and in vivo activity of liposome-encapsulated gentamicin. Antimicrob Agents Chemother 34:235-240.
  551. Talan DA. 2001. Clinical perspectives on new antimicrobials: focus on fluoroquinolones. Clin Infect Dis 32(Suppl 1):S64-S71.
  552. Tamayo M, Su-Leuor R, Santos Sanches I, et al. 1999. Patterns and mechanisms of resistance to beta-lactams and betalactamase inhibitors in uropathogenic Escherichia coli isolated from dogs in Portugal. J Clin Microbiol 37:2337-2342.
  553. Tang S, Zhou Y, Li R, et al. 2007. Pharmacokinetics and lung-targeting characterization of a newly formulated enrofloxacin preparation. J Vet Pharmacol Ther 30:443-450.
  554. Tarlow JM, Rudloff E, Lichtenberger M, et al. 2005. Emergency presentations of 4 dogs with suspected neurologic toxoplasmosis. J Vet Emerg Crit Care 15:119-127.
  555. Tasker S, Caney SMA, Day MJ, et al. 2006. Effect of chronic feline immunodeficiency infection and efficacy of marbofloxacin treatment, on "Candidatus Mycoplasma haemominutum" infection. Microb Infect 8:653-661.
  556. Tasker S, Caney SMA, Day MJ, et al. 2006b. Effect of chronic FIV infection, and efficacy of marbofloxacin treatment, on Mycoplasma haemofelis infection. Vet Microbiol 117:169-179.
  557. Tasker S, Helps CR, Day MJ, et al. 2004. Use of a Taqman PCR to determine the response of Mycoplasma haemofelis infection to antibiotic treatment. J Microbiol Methods 56:63-71.
  558. Tejedor MT, Martín JL, Navia M, et al. 2003. Mechanisms of fluoroquinolone resistance in Pseudomonas aeruginosa isolates from canine infections. Vet Microbiol 94:295-301.
  559. Ten Voorde G, Broeze J, Hartman EG, et al. 1990. The influence of the injection site on the bioavailability of ampicillin and amoxicillin in beagles. Vet Q 12:73-79.
  560. Teng RL, Girard D, Gootz TD, et al. 1996. Pharmacokinetics of trovafloxacin (CP-99, 219) a new quinolone in rats, dogs, and monkeys. Antimicrob Agents Chemother 40:561-566.
  561. Tenover FC. 1992. Bauer and Kirby meet Watson and Crick. Antimicrobial susceptibility testing in the molecular era. ASM News 58:669-672.
  562. Teshager T, Dominguez L, Moreno ME, et al. 2000. Isolation of an SHV-12 β-lactamase-producing Escherichia coli strain from a dog with recurrent urinary tract infections. Antimicrob Agents Chemother 44:3483-3484.
  563. Thompson GW. 1990. Possible sulfamethoxazole/trimethoprim-induced hepatic necrosis in a dog. Can Vet J 31:530.
  564. Thompson J. 2000. Enrofloxacin. Compend Cont Educ Pract Vet 22:602-605.
  565. Thomson KH, Rantala MHJ, Viita-Aho TK, et al. 2009. Condition-based use of antimicrobials in cats in Finland: results from two surveys. J Feline Med Surg 11:462-466.
  566. Thornton JR, Martin PJ. 1997. Pharmacokinetics of cephalexin in cats after oral administration of the antibiotic in tablet and paste preparations. Aust Vet J 75:439-440.
  567. Tilley BC, Trentham DE, Leisen JCC, et al. 1995. Minocycline in rheumatoid arthritis. Ann Intern Med 122:81-89.
  568. Tilmant L, Brown MP, Gronwall RR. 1985. Pharmacokinetics of ticarcillin in the dog. Am J Vet Res 46:479-481.
  569. Toma S, Colombo S, Cornegliani L, et al. 2008. Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma: an open controlled study. J Small Anim Pract 49:384-391.
  570. Tomasz A. 1994. Multiple-antibiotic-resistant pathogenic bacteria. A report on the Rockefeller University workshop. N Engl J Med 330:1247-1251.
  571. Tomlin J, Pead MJ, Lloyd DH, et al. 1999. Methicillin-resistant Staphylococcus aureus infection in 11 dogs. Vet Rec 144:60-64.
  572. Toutain PL. 2003. Antibiotic treatment of animals—a different approach to rational dosing. Vet J 165:98-100.
  573. Tras B, Maden M, Bas AL, et al. 2001. Investigation of biochemical and haematological side-effects of enrofloxacin in dogs. J Vet Med 48:59-63.
  574. Trepanier LA. 2004. Idiosyncratic toxicity associated with potentiated sulfonamides in the dog. J Vet Pharmacol Ther 27:129-138.
  575. Trepanier L. 2009. Idiopathic inflammatory bowel disease in cats: rational treatment selection. J Feline Med Surg 11:32-38.
  576. Trepanier LA, Danhof R, Toll J, et al. 2003. Clinical findings in 40 dogs with hypersensitivity associated with administration of potentiated sulfonamides. J Vet Intern Med 17:647-652.
  577. Trettien AL, Kram MA. 1994. Primor once-a-day canine antibacterial has important advantages. Top Vet Med 5:4-8.
  578. Trettien AL, Kram MA. 1994. Primor once-a-day canine antibacterial has important advantages. SmithKline Beecham Animal Health Technical Bulletin 1-5.
  579. Trott DJ, Moss SM, See AM, et al. 2007. Evaluation of disc diffusion and MIC testing for determining susceptibility of Pseudomonas aeruginosa isolates to topical enrofloxacin/silver sulfadiazine. Aust Vet J 85:464-466.
  580. Trudel JL, Wittnich C, Brown RA. 1994. Antibiotics bioavailability in acute experimental pancreatitis. J Am Coll Surg 178:475-479.
  581. Turk J, Maddox C, Fales W, et al. 1998. Treatment of canine diarrhea with antibiotics. J Am Vet Med Assoc 212:1735-1736.
  582. Turk J, Maddox C, Fales W, et al. 1998. Treatment of canine diarrhea with antibiotics. Vet Forum Sept:20-21.
  583. Turnidge J. 1999. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58:29-36.
  584. Turnidge JD. 1998. The pharmacodynamics of β-lactams. Clin Infect Dis 27:10-22.
  585. Twedt DC, Diehl KJ, Lappin MR, et al. 1997. Association of hepatic necrosis with trimethoprim sulfonamide administration in 4 dogs. J Vet Intern Med 11:20-23.
  586. Ubeeva IP, Nikolaev SM, Sambueva ZG. 1989. Effect of antihepatotoxic tea on the course of drug-induced hepatitis. Antibiot Khimioter 34:859-862.
  587. Vance S. 2000. Clarity on enrofloxacin dosing. Vet Forum 57:36.
  588. Vancutsem PM, Babish JG, Schwark WS. 1990. The fluoroquinolone antimicrobials: structure, antimicrobial activity, pharmacokinetics, clinical use in domestic animals and toxicity. Cornell Vet 80:173-186.
  589. Van den Bogaard AE, Stobberingh EE. 1999. Antibiotic usage in animals. Impact on bacterial resistance and public health. Drugs 58:589-607.
  590. Van den Bulck K, Decostere A, Gruntar I, et al. 2005. In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salmonis. Antimicrob Agents Chemother 49:2997-3000.
  591. Van den Hoven R. 1997. A multi-centre observational study on the efficacy of Dicural Palatabs (difloxacin) for the treatment of canine cystitis. J Vet Pharmacol Ther 20(Suppl 1):185-186.
  592. Van Schoyck M. 1998. Susceptibility of canine and feline bacteria to Clavamox: results of a 1994-1996 five-school study. Pfizer Anim Health Tech Bull Sep:1-4.
  593. Varzi HN, Esmailzadeh S, Morovvati H, et al. 2007. Effect of silymarin and vitamin E on gentamicin-induced nephrotoxicity in dogs. J Vet Pharmacol Ther 30:477-481.
  594. Vasilopulos RJ, Mackin A, Lavergne SN, et al. 2005. Nephrotic syndrome associated with administration of sulfadimethoxine/ormetoprim in a Doberman. J Small Anim Pract 46:232-236.
  595. Vial T, Biour M, Descotes J, et al. 1997. Antibiotic-associated hepatitis: update from 1990. Ann Pharmacother 31:204-220.
  596. Villar D, Knight MK, Holding J, et al. 1995. Treatment of acute isoniazid overdose in dogs. Vet Hum Toxicol 37:473-477.
  597. Vilmanyi E, Kung K, Riond JL, et al. 1996. Clarithromycin pharmacokinetics after oral administration with or without fasting in crossbred beagles. J Small Anim Pract 37:535-539.
  598. Vinayak A, Greene CE, Moore PA, et al. 2004. Clinical resolution of Brucella canis-induced ocular inflammation in a dog. J Am Vet Med Assoc 224:1804-1807, 1788-1789.
  599. Von Eiff C, Peters G. 1999. Comparative in-vitro activities of moxifloxacin, trovafloxacin, quinupristin/dalfopristin and linezolid against staphylococci. J Antimicrob Chemother 43:569-573.
  600. von Keutz E, Rühl-Fehlert C, Drommer W, et al. 2004. Effects of ciprofloxacin on joint cartilage in immature dogs immediately after dosing and after a 5-month treatment-free period. Arch Toxicol 78:418-424.
  601. Walker AL, Jang SS, Hirsh DC. 2000. Bacteria associated with pyothorax of dogs and cats: 98 cases (1989-1998). J Am Vet Med Assoc 216:359-363.
  602. Walker RD. 2000. Fluoroquinolones, pp 315-338. In Prescott JF, Baggot JD, Walker RD (eds): Antimicrobial therapy in veterinary medicine, ed 3. Iowa State University Press, Ames, IA.
  603. Walker RD. 2000. The use of fluoroquinolones for companion animal antimicrobial therapy. Aust Vet J 78:84-90.
  604. Walker RD, Stein GE, Budsberg SC, et al. 1989. Serum and tissue fluid norfloxacin concentrations after oral administration of the drug to healthy dogs. Am J Vet Res 50:154-157.
  605. Walker RD, Stein GE, Hauptman JC. 1990. Serum and tissue cage fluid concentrations of ciprofloxacin after oral administration of the drug to healthy dogs. Am J Vet Res 51:896-900.
  606. Walker RD, Stein GE, Hauptman JG, et al. 1992. Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res 53:2315-2319.
  607. Wanke MM, Delpino MV, Baldi PC. 2006. Use of enrofloxacin in the treatment of canine brucellosis in a dog kennel (clinical trial). Theriogenology 66:1573-1578.
  608. Warren AL, Townsend KM, King T, et al. 2001. Multi-drug resistant Escherichia coli with extended-spectrum β-lactamase activity and fluoroquinolone resistance isolated from clinical infections in dogs. Aust Vet J 79:621-623.
  609. Warrick JM, Inskeep GA, Yonkers TD, et al. 2000. Effect of clindamycin hydrochloride on oral malodor, plaque, calculus, and gingivitis in dogs with periodontitis. Vet Ther 1:5-16.
  610. Watson AD, Maddison JE. 2001. Systemic antibacterial drug use in dogs in Australia. Aust Vet J 79:740-746.
  611. Watson ADJ. 1991. Chloramphenicol: 2. Clinical pharmacology in dogs and cats. Aust Vet J 68:2-5.
  612. Watson ADJ. 1992. Bioavailability and bioinequivalence of drug formulations in small animals. J Vet Pharmacol Ther 15:151-159.
  613. Watson PM. 2002. Idiosyncratic reaction to enrofloxacin in cats. Vet Rec 150:556.
  614. Watson PM, Bell GD, Webster CMM, et al. 1998. Fluoroquinolone susceptibility of S. typhimurium DT104. Vet Rec 142:374.
  615. Watts JL, Salmon SA, Sanchez MS, et al. 1997. In vitro activity of premafloxacin, a new extended-spectrum fluoroquinolone against pathogens of veterinary importance. Antimicrob Agents Chemother 41:1190-1192.
  616. Watts JL, Yancey RJ. 1994. Identification of veterinary pathogens by use of commercial identification systems and new trends in antimicrobial susceptibility testing of veterinary pathogens. Clin Microbiol Rev 7:346-356.
  617. Weese JS. 2006. Investigation of antimicrobial use and the impact of antimicrobial use guidelines in a small animal veterinary teaching hospital: 1995-2004. J Am Vet Med Assoc 228:553-558.
  618. Weese JS. 2008. Issues regarding the use of vancomycin in companion animals. J Am Vet Med Assoc 233:565-567.
  619. Wegener HC, Aarestrup FM, Gerner-Smidt P, et al. 1999. Transfer of antibiotic resistant bacteria from animals to man. Acta Vet Scand 92(Suppl):51-57.
  620. Weiss DJ, Adams LG. 1987. Aplastic anemia associated with trimethoprim-sulfadiazine and fenbendazole administration in a dog. J Am Vet Med Assoc 191:1119-1120.
  621. Westermarck E, Frias R, Skrzypczak T. 2005. Effect of diet and tylosin on chronic diarrhea in beagles. J Vet Intern Med 19:822-827.
  622. Westermarck E, Skrzypczak T, Harmoinen J, et al. 2005. Tylosin-responsive chronic diarrhea in dogs. J Vet Intern Med 19:177-186.
  623. Westfall DS, Jensen WA, Reagan WJ, et al. 2001. Inoculation of two genotypes of Haemobartonella felis (California and Ohio variants) to induce infection in cats and the response to treatment with azithromycin. Am J Vet Res 62:687-691.
  624. Westfall DS, Twedt DC, Steyn PF, et al. 2001. Evaluation of esophageal transit of tablets and capsules in 30 cats. J Vet Intern Med 15:467-470.
  625. Westfall DS, Twedt DC, Steyn PF, et al. 2001. Evaluation of the passage of tablets and capsules through the esophagus of cats, p 838. In Proceedings of the 19th Annual ACVIM Forum, Denver, CO.
  626. White SD, Rosychuck RAW, Reinke SI. 1992. Use of tetracycline and niacinamide for treatment of autoimmune skin disease in 31 dogs. J Am Vet Med Assoc 200:1497-1500.
  627. Whittem TL, Johnson AL, Smith CW, et al. 1999. Effect of perioperative prophylactic antimicrobial treatment in dogs undergoing elective orthopedic surgery. J Am Vet Med Assoc 215:212-216.
  628. Wiebe V, Hamilton P. 2002. Fluoroquinolone-induced retinal degeneration in cats. J Am Vet Med Assoc 221:1568-1571.
  629. Willard MD, Berridge B, Braniecki A, et al. 1998. Possible antibiotic-associated colitis in a dog. J Am Vet Med Assoc 213:1775-1779.
  630. Williams JD, Naber KG, Bryskier A, et al. 2001. Classification of oral cephalosporins. A matter for debate, Int J Antimicrob Agents 17:443-450.
  631. Williamson NL, Frank LA, Hnilica KA. 2002. Effects of short-term trimethoprim-sulfamethoxazole administration on thyroid function in dogs. J Am Vet Med Assoc 221:802-806.
  632. Wilson BJ, Norris JM, Malik R, et al. 2006. Susceptibility of bacteria from feline and canine urinary tract infections to doxycycline and tetracycline concentrations attained in urine four hours after oral dosage. Aust Vet J 84:8-11.
  633. Wilson D. 2002. Feline visual changes associated with enrofloxacin. Can Vet J 43:163.
  634. Wilson RC, Duran SH, Horton CR, et al. 1989. Bioavailability of gentamicin in dogs after intramuscular or subcutaneous injections. Am J Vet Res 50:1748-1750.
  635. Winokur PL, Brueggemann A, DeSalvo DL, et al. 2000. Animal and human multi-dog resistant, cephalosporin-resistant salmonella isolates expressing a plasmid-mediated CMY-2 AmpC beta-lactamase. Antimicrob Agents Chemother 44:2777-2783.
  636. Wolfson JS, Hooper DC. 1989. Fluoroquinolone antimicrobial agents. Clin Microbiol Rev 2:378-424.
  637. Woodford N, Adebiyi A-M, Palepou M-F, et al. 1998. Diversity of VanA glycopeptide resistance elements in enterococci from humans and nonhuman sources. Antimicrob Agents Chemother 42:502-508.
  638. Wright K, Tyler J. 2003. Recognizing metronidazole toxicosis in dogs. Vet Med 98:410-418.
  639. Wright LC, Horton CR Jr, Jernigan AD, et al. 1991. Pharmacokinetics of gentamicin after intravenous and subcutaneous injection in obese cats. J Vet Pharmacol Ther 14:96-100.
  640. Wulansari R, Wijaya A, Ano H, et al. 2003. Lymphocyte subsets and specific IgG antibody levels in clindamycin-treated and untreated dogs experimentally infected with Babesia gibsoni. J Vet Med Sci 65:579-584.
  641. Yabe K, Murakami Y, Nishida S, et al. 2001. A non-arthropathic dose and its disposition following repeated oral administration of ofloxacin, a new quinolone antimicrobial agent, to juvenile dogs. J Vet Med Sci 63:867-872.
  642. Yabe K, Satoh H, Ishii Y, et al. 2004. Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent. Vet Pathol 41:673-681.
  643. Yabe K, Yoshida K, Yamamoto N, et al. 1997. Diagnosis of quinolone-induced arthropathy in juvenile dogs by use of magnetic resonance (MR) imaging. J Vet Med Sci 59:597-599.
  644. Yağci BB, Ural K, Öcal N, et al. 2008. Azithromycin therapy of papillomatosis in dogs: a prospective, randomized, double-blinded, placebo-controlled clinical trial. Vet Dermatol 19:194-198.
  645. Yoshida K, Matsubayashi K, Sekiguchi M, et al. 1997. Toxicological evaluation and disposition of DV-7751A, a new quinolone antimicrobial agent, administered orally to dogs and monkeys. Chemotherapy 43:332-339.
  646. Yoshida K, Yabe K, Nishida S, et al. 1998. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 21:128-132.
  647. Yu LP, Smith GN, Brandt KD, et al. 1992. Reduction in the severity of canine osteoarthritis by prophylactic treatment with oral doxycycline. Arthritis Rheum 35:1150-1159.
  648. Yu-Speight AW, Kern TJ, Erb HN. 2005. Ciprofloxacin and ofloxacin aqueous humor concentrations after topical administration in dogs undergoing cataract surgery. Vet Ophthalmol 8:181-187.
  649. Zaghlol HA, Brown SA. 1988. Single- and multiple-dose pharmacokinetics of intravenously administered vancomycin in dogs. Am J Vet Res 9:1637-1640.
  650. Zdovc I, Ocepek M, Pirs T. 2004. Microbiological features of Staphylococcus schleiferi subsp. coagulans, isolated from dogs and possible misidentification with other canine coagulase-positive staphylococci. J Vet Med B Infect Dis Vet Public Health 51:449-454.
  651. Zetner K, Rothmueller G. 2002. Treatment of periodontal pockets with doxycycline in beagles. Vet Ther 3:441-452.
  652. Zetner K, Schmidt H, Pfeiffer S. 2003. Concentrations of clindamycin in the mandibular bone of companion animals. Vet Ther 4:166-171.
  653. Zetner K, Thiemann G. 1993. The antimicrobial effectiveness of clindamycin in diseases of the oral cavity. J Vet Dent 10:6-9.
  654. Zhang SQ, Zhang FL, Xing J, et al. 2003. [Metabolism of roxithromycin in dogs]. Yao Xue Xue Bao 38:374-379.
  655. Zygner W, Jaros D, Gójska-Zygner O, et al. 2008. Azithromycin in the treatment of a dog infected with Giardia intestinalis. Pol J Vet Sci 11:231-234.